,expected_information_gain
should,0.05100053520130543
be,0.03878000512198121
following,0.02113617970129711
plasma,0.020722882244210594
interact,0.02025292204170215
:,0.019742020283875616
protease,0.016823019984437915
caution,0.01603188056086924
may,0.013164488030695254
effects,0.012979529087605135
levels,0.012508839876909206
oral,0.012240404785801906
%,0.011921951381587914
",",0.011828395529154712
hiv,0.011642182605834828
thyroid,0.01159566702839332
medications,0.011407994434273983
johns,0.011233472525997712
classified,0.011174114740980734
contin,0.011151911705344242
include,0.011134588992619099
(,0.011003961696251063
),0.010996720674924743
ms,0.010873552921702112
steroids,0.01071940908800495
unreliable,0.010696683788576689
man,0.010587499534161604
inhibitors,0.01055300859596775
*,0.010549836736960971
st.,0.01041782078894693
auc,0.01037373912308015
hydrate,0.010151971785199332
chloral,0.010151971785199332
ie,0.009909939345244312
concentrations,0.00977413421786233
wort,0.00965498118447683
warfarin,0.009517615005837254
is,0.009412531533873336
dietary,0.009387740229031771
hot,0.009385756054520189
vaccine,0.00937424379544649
influenza,0.00937424379544649
monoamine,0.009371626981016679
elements,0.009366101517992553
narcotics,0.009366101517992553
deficiencies,0.009366101517992553
triclofos,0.009366101517992553
inhalation,0.009366101517992553
oxolinic,0.009366101517992553
overdosage,0.009352146611632972
weather,0.009347210311532184
anabolic,0.009347210311532184
affecting,0.009337343049439562
acid,0.009334685444733926
;,0.009328800032453954
nalidixic,0.00930421531253045
no,0.009302450071650759
mefenamic,0.009258442960303093
with,0.009189968544723315
of,0.009164060717828493
oxidase,0.009022912133492711
determinations,0.008943354453275432
virus,0.008919270517920297
found,0.008798050793674017
metabolism,0.008751908159985389
response,0.008688103820841953
drugs,0.008676162124337639
cyp3a4,0.008648187485816194
sodium,0.008622008462033648
reportedly,0.008563204389538615
not,0.008462707382835166
hepatotoxic,0.008434968015309185
expected,0.008291923281573133
cyp,0.0080881495545998
time,0.007970465720805286
long,0.007960205611598492
acting,0.007932324898213272
aminosalicylic,0.007902110559097952
ethacrynic,0.007835782640721045
trimethoprim/sulfamethoxazole,0.007799729740646133
c,0.007772136323237255
enzymes,0.00775609959502177
action,0.0076917024844118664
prothrombin,0.0076816773260590665
prolonged,0.007619214600751212
increase,0.007237897178640318
absorption,0.007235567615832883
decreased,0.007228002766709651
patients,0.007182399023423547
that,0.006946916664501646
medicines,0.006640014405955963
induction,0.00656821559319587
blood,0.0065630761948398675
clearance,0.006430369718829043
enhance,0.006329463805649027
vitamin,0.006207165749631871
in,0.0059414795264154385
studies,0.005884189262001183
therefore,0.005786162408096818
4,0.005703285760694898
other,0.005511864640146746
5,0.005497038365846252
interactions,0.00548591626268391
recommended,0.005440695611608204
additive,0.005388286872117787
depression,0.005347192215452434
neuromuscular,0.005315376929686644
pharmacokinetics,0.0053116981620981996
cmax,0.005278277143152765
blocking,0.0052699471418882204
local,0.005205422000821969
receiving,0.005204707664189789
depressants,0.0051937525891149194
supplements,0.005170157291839672
type,0.005059469183174348
cns,0.005036664311540595
by,0.005016177948131584
because,0.005012569725870275
central,0.004901030725276034
nondepolarizing,0.004793927768070083
monitored,0.004750156399901173
due,0.00468415790314447
dose,0.004657061738516433
3,0.004604602332769159
used,0.004474220708831189
were,0.004465578072801346
presence,0.004378490665549739
interaction,0.004343346658317149
approached,0.004327277817455455
if,0.004271020372744072
narcotic,0.004260813159239207
decrease,0.004246388807198964
others,0.004218728552694562
salts,0.004211435514775097
metabolized,0.004151860755756909
inducers,0.004130666621094292
when,0.00410873480431706
antihypertensive,0.004010354520410209
colistimethate,0.003950955956058433
or,0.0039318604700814275
did,0.003907044024020978
anti-diarrhea,0.0038752949574629714
kaolin-pectin,0.0038752949574629714
absorbent-type,0.0038752949574629714
bleeding,0.003823083568984087
are,0.003805191127822738
general,0.003789439497071223
evaluating,0.003723214845873457
1,0.0036662370286730805
administered,0.00361839250840168
increased,0.003607276756826261
certain,0.0035210812701996774
advised,0.0034629377798531813
nervous,0.0034593381699146164
1c,0.0034428980136111953
potassium,0.0034395591739724285
antiarrhythmics,0.0034327635771025378
concomitantly,0.0033965932093295015
enzyme,0.0033508294053128385
such,0.0033269476525950026
chloride,0.0033253889836661887
grapefruit,0.0032627140391565668
juice,0.0032627140391565668
serious,0.003262062936664978
reported,0.0032525234889231314
was,0.0032433669875207016
estradiol,0.0032375341740209507
pharmacokinetic,0.003135631780662007
before,0.003120441229573556
the,0.0031162906580994854
excretion,0.0031095077637701696
considered,0.003082369427889642
you,0.003073524268686345
antifungals,0.0030622223429103146
mg,0.003011958426701211
including,0.0029974164658999047
kt,0.0029893546381082325
levonorgestrel/ethinyl,0.0029893546381082325
to,0.0029882446424145392
muscle,0.0028938501660970006
relaxants,0.0028775907406555223
analgesics,0.0028690150773709178
affect,0.002850522416666945
taken,0.0028379928246057284
tubular,0.0027646210976568497
cytochrome,0.0027634091981477704
adjustment,0.0027619489887451554
within,0.0027599938987628025
half-life,0.002737633483204993
azole,0.00273298339867567
effect,0.0027217651840250046
combination,0.0027207836219412806
approximately,0.002665732997427561
therapy,0.0026566131609899735
mao,0.0026423140018665414
resulted,0.0026212836597536704
drug,0.0026167847053397697
narrow,0.002608738141029354
strong,0.0026033497349268186
and,0.0025891631338148535
acetylsalicylic,0.002567323229314411
needed,0.0025603729394308994
antidepressants,0.0025578869326081666
metabolite,0.0025550750438072534
been,0.002539466284548375
.,0.0025374305396125285
3a4,0.002533599867540426
any,0.002530017356762504
induce,0.002516839561262918
on,0.0025056552506927954
as,0.00249614977011714
thinners,0.0024947094636579292
can,0.002477425070090522
e.g.,0.002469431612709738
depressant,0.002462451300784707
hours,0.002457302089480029
performed,0.0024409363468909095
20,0.0024380076329959532
exercised,0.002423590126258701
fatal,0.002421110453155184
birth,0.0024138632784131975
syndrome,0.0023997159506752297
produce,0.002384931653931277
false,0.002383407081468669
pancreatic,0.0023769644306982363
para-aminobenzoic,0.0023759387318444958
sulfa,0.0023759387318444958
sunscreens,0.0023759387318444958
-containing,0.0023759387318444958
block,0.002366302824939659
significant,0.0023650115992105425
respectively,0.0023591999726630952
pills,0.00235826211532264
p450,0.0023561642181726405
potentiated,0.0023532800891182815
tricyclic,0.0023516943016994585
beta,0.0023493932161696707
avoided,0.002342221902505548
index,0.002323151391162237
a,0.002302578806805622
bioavailability,0.0022982026274223077
your,0.0022798023734809103
significantly,0.0022746028080873337
it,0.0022673514435938014
isoenzyme,0.0022617415540782115
risk,0.0022505514323893916
since,0.002245320625906433
excessive,0.002237976082212545
use,0.0022157144745932333
give,0.0021956588464094873
administering,0.0021950539366513144
care,0.0021887676796480404
vitro,0.0021858400840355507
retinyl,0.0021736603938677934
reduce,0.0021664132141760994
doctor,0.0021478628277505907
hepatic,0.002123077278202712
healthy,0.0021199332523476055
tell,0.002104968156068865
reports,0.002077029198476299
contraindicated,0.0020618722079974727
adrenergic,0.002055130814973105
ergot-type,0.0020415336899362035
clinical,0.0020289540512641313
examples,0.0020166167559078074
daily,0.001994610336446434
theoretical,0.001964499972990419
vision,0.0019570551850541795
blurred,0.0019570551850541795
binding,0.001950832094789301
have,0.0019486128462922192
suggest,0.0019438852102563464
ergotamine-containing,0.0019425674696524897
proliferation,0.0019414337018156536
based,0.0019342630212574319
avoid,0.0019245485427491493
exposure,0.0019199939922380782
control,0.0019181636157394877
hypotension,0.0019011060459794837
dosage,0.001886675794867454
pain,0.0018838741163025308
active,0.0018825099887154195
potent,0.0018604532902531945
cause,0.0018572698477244964
result,0.00185070839219581
co-administration,0.001844662879732173
dry,0.0018383333238757293
administration,0.0018221882318161242
possible,0.0018206808101410843
skeletal,0.0018192651235164892
associated,0.0018078681708617594
causing,0.0018077563657308282
taking,0.0018065497110708595
reactions,0.0018058456753250463
severe,0.00180079428065405
chboramphenicol,0.0017895614184375574
occurring,0.0017895614184375574
hyperpyrexia,0.0017880301369204155
sedative,0.001785340774269617
colistemethate,0.0017836006478476607
reuptake,0.0017791535295603733
concentration,0.001772444780360427
mouth,0.001770786054418494
diminish,0.0017698728826665011
mean,0.0017625160139209672
carefully,0.001751770287887311
period,0.001751550005132163
selegiline,0.0017365492666313598
sleeping,0.0017314261084320215
30,0.0017290186112327577
b1,0.0017290113828505316
serotonin,0.0017187934446191155
study,0.0017152906170236903
pressor,0.001711863481706155
nicotinic,0.0017095224931797937
temperature,0.0017093833702415129
secretion,0.0016991956148026954
sedation,0.0016887185395233484
least,0.0016800383986803613
evidence,0.0016776843024390864
serotoninergic,0.001668287187061912
e.,0.001665252418448504
loop,0.0016637551363540837
end,0.0016605585809359447
consequently,0.001659950393082421
will,0.0016586344396665176
closely,0.0016529539229281909
angiotensin-converting,0.0016434128735756115
diuretics,0.0016371670540361594
humidity,0.0016366203377385924
dental,0.0016366203377385924
potential,0.0016249986231717806
nonsteroidal,0.0016219402322991128
g.,0.0016137649029946965
cyp2d6,0.0016073459524450495
adrenocortical,0.0015994986091725227
agonist,0.001591490174580934
antagonized,0.0015765482896562544
known,0.0015746054270303622
prothrom-bin,0.0015696139442755719
preparations,0.0015668611325049264
treatment,0.0015540191567207096
diet,0.0015503317399030436
under-dosage,0.0015503317399030436
-,0.0015494745049311476
blockers,0.0015441361239361129
antiparkinsonian,0.0015383789481865362
intraconazole,0.0015192867895603701
shown,0.001508314957931356
an,0.00150623217122825
coma,0.0015053405494555028
cautiously,0.0015039922756056034
nonselective,0.001503592967054268
acidic,0.0015027189605480995
basic,0.0015027189605480995
observation,0.001499133273909159
appropriate,0.001490050619837091
test,0.001487812022303192
epithelium,0.0014800141517383736
required,0.0014737250230031362
drug-drug,0.0014698243482016426
agents,0.001464518776698287
close,0.0014641197692336627
had,0.001461426861831261
b,0.0014524787357076407
activity,0.0014498713938638774
who,0.0014473014692882868
adverse,0.0014405607717252744
modest,0.0014350846395405625
warranted,0.0014347563606492697
psychotropic,0.001428737572571892
systemic,0.0014278957409646909
potentiate,0.0014241523557433355
agonists,0.001420013896352601
initiated,0.0014178810822018661
which,0.0014160116910429954
gastrointestinal,0.0014123813409759878
data,0.001410370106300629
undertaken,0.0014052927020131722
intake,0.001404156438804094
sinus,0.0013939374712242936
decongestant,0.0013939374712242936
allergy,0.0013939374712242936
3a,0.0013918464548986487
necessary,0.0013916619220347703
substances,0.0013903889810182868
hypoglycemic,0.001388895779257604
incidence,0.0013886458355458764
system,0.001377047217252847
dopamine,0.001374161231847415
many,0.0013723664666824842
does,0.0013718974968713882
psychotic,0.001370212630359413
inhibit,0.0013674606366823605
using,0.0013654945358310133
sedating,0.001359807535530666
extreme,0.0013562668226837493
at,0.0013461600202142598
patient,0.001342092479170387
serum,0.001339428307986612
i.e.,0.0013343801494967167
effectiveness,0.0013262057461816967
2,0.001324362796654488
more,0.001323785648128517
multiple,0.0013162285056059764
cold,0.001309724051146599
delay,0.0013021116730238536
episodes,0.001296784348067903
extensively,0.0012955991426116809
substrates,0.0012908657931611778
inhibits,0.0012812727288282755
volunteers,0.00127999113471855
24,0.0012709216880590901
clinically,0.0012682222646566155
antipsychotic,0.0012679629394675151
conducted,0.0012675641851077613
for,0.001264197952613566
interfere,0.0012561720497904494
hydrochloride,0.001248284251915921
has,0.0012421226639094396
decreases,0.001241395387751032
substrate,0.0012410861109146687
[,0.0012383105852540321
],0.0012383105852540321
secondary,0.0012374425975534287
agonist/antagonist,0.0012373184746575783
selective,0.0012331693729321636
sympathomimetic,0.001232197051082795
death,0.0012320824272020747
single,0.001226274570329533
increases,0.0012241017879630611
related,0.0012236759854107326
make,0.0012205253130164184
referred,0.0012205253130164184
like,0.0012204223093666977
exceed,0.0012192113714531994
course,0.0012147702272817806
cyp3a,0.0012120023748918296
ovarian,0.0012083108574401091
below,0.001207020449338847
antianxiety,0.0012036378025243044
available,0.0011987342051950067
complications,0.0011957498674430855
concurrent,0.001195254976968041
macrolide,0.0011932670855143712
exposed,0.001191103989798492
choline,0.0011908966713469749
magnesium/choline,0.0011908966713469749
a-blockers,0.0011906723823149612
anti-infectives,0.0011906723823149612
calcium-channel,0.0011906723823149612
synthetase,0.0011906723823149612
dose-dependent,0.0011888754726172568
listed,0.0011872331354370047
antagonize,0.0011830389462748059
alone,0.0011811906529405336
range,0.0011781495879513715
being,0.0011761260497117343
concurrently,0.0011694550211727162
renal,0.001165064571956309
mg/day,0.0011646709347732376
thiazide,0.0011589623645766878
anticipated,0.0011588583124929608
containing,0.001157010541884107
blood-glucose-lowering,0.0011569628317362746
must,0.0011550187499237419
resulting,0.0011541820286041782
opioid,0.0011534740682680455
k,0.0011483502506710597
therapeutic,0.0011453178857295798
produced,0.0011425888021356911
inducer,0.0011423295953092438
during,0.0011413523780112733
require,0.0011355209441844538
profound,0.0011341391036857607
sometimes,0.001123960364297294
steady-state,0.0011237419174452423
exhibit,0.0011233942921202722
retard,0.0011230940236753861
trials,0.0011210167893963563
than,0.001117906958009618
function,0.0011167616532503644
each,0.0011151262437713028
days,0.001114088334558283
polymyxin,0.0011110851777903497
amphotericin,0.0011054186675545363
ph,0.0011027751466895497
experience,0.0010996318542590977
weakness,0.0010985974259268838
treated,0.001095717211386349
cns-depressant,0.0010933756957181018
between,0.001085930540272395
80,0.001085458552396057
magnesium,0.0010851418904874732
coadministration,0.001084755667597359
results,0.0010830968323951584
showed,0.0010798827330483762
monitoring,0.0010775781746211743
glaucoma,0.001075004756829312
ophthalmic,0.001075004756829312
ergot,0.0010739674644048014
rarely,0.0010721074680486442
extent,0.0010719130050955705
lower,0.0010708499509762825
most,0.001067593741331585
veratrum,0.0010663070273408959
important,0.0010628465362709782
folic,0.0010611874518602349
60,0.0010599256915976296
acute,0.0010595746552242158
reduced,0.001055173499703077
subsalicylate,0.0010510464500939065
bismuth,0.0010510464500939065
eg,0.0010472878061633661
natriuretic,0.001045562992333715
induced,0.0010452234393990567
drowsiness-causing,0.001041470952202861
sleep,0.001041470952202861
drowsy,0.001041470952202861
aid,0.001041470952202861
anti-depressants/anti-anxiety,0.001041470952202861
overactive,0.001041470952202861
phenothiazine,0.001041470952202861
incoordination,0.001036238258812272
hyperreflexia,0.001036238258812272
medicine,0.0010340445526554332
mixed,0.001032062841322734
ethyl,0.0010312206937784785
max,0.0010292232255117995
dosing,0.0010273729449057356
etc,0.0010251373777908634
discontinued,0.0010248526314319273
hallucinations,0.001023943146107098
doubled,0.0010233304600966164
le,0.0010233304600966164
auc0-,0.0010233304600966164
women,0.0010206193601322022
cations,0.0010108551396746934
ace,0.0010088059170676456
actions,0.0010049145669175363
elimination,0.0010008570465820377
10,0.0010001503116309207
stable,0.0009985455756214012
together,0.00099610626767066
some,0.0009910267110184723
blockade,0.0009906209101833152
50,0.0009905258550957363
respiratory,0.0009850079748295881
investigated,0.0009818531931101715
reacts,0.0009817478127576162
neutral,0.0009817478127576162
enhanced,0.0009794723708501651
medication,0.0009794036637542636
diuretic,0.000976875849843517
influence,0.0009753231693707676
analgesic,0.0009748482915105106
platelet,0.0009709765797999426
received,0.0009662195075426094
diabetic,0.0009637433803714179
infusion,0.0009614883349003955
either,0.0009591474079547746
commonly,0.0009575569174099519
--,0.000955234983108455
initiating,0.0009540642543158784
occur,0.0009483668296670356
synergism,0.0009460292590519614
generally,0.0009388612309584321
adjusted,0.0009355957321774966
intestinal,0.0009353744595709257
conjugated,0.0009321234790554689
analog,0.0009321234790554689
possibility,0.000931750026772038
danger,0.0009315265589819877
human,0.0009308191286399037
protein,0.000926693643026888
cholinesterase,0.0009235380016966444
s,0.0009232508898984193
faster,0.0009212524315140858
la,0.0009205620076295773
detrol,0.0009205620076295773
calcium,0.0009158176986361344
hypotensive,0.0009157451141679207
once,0.0009135725123917693
cyp2c9,0.0009132536026900118
alcohol,0.0009132216807914428
anticholinergic,0.0009109149078413425
intravenous,0.0009107172881659409
potentiating,0.0009104223835019187
elevated,0.000904104572557296
reasonable,0.0009031074643249815
begins,0.0009031074643249815
expect,0.0009031074643249815
transcriptase,0.0009023112577591919
glyceryl,0.0009023112577591919
trinitrate,0.0009023112577591919
dinitrate,0.0009023112577591919
acidifying,0.0009020176382769085
hypertension,0.000898544639636234
specific,0.000894030491071951
latter,0.0008920256188937881
accordingly,0.0008913975644138095
ferrous,0.0008905425369133413
tablets,0.0008904716180391237
urinary,0.0008867919345697528
conduction,0.0008836411817084722
until,0.000882337242299247
acetate,0.0008801978464129112
nitrous,0.0008756191626677623
state,0.000875300589864958
well,0.0008744831070304215
2d6,0.0008744307199805013
elapse,0.0008739602722532824
titrated,0.0008709215193996034
these,0.000869958063031917
antidiabetic,0.0008674719719307111
interval,0.0008610197923392127
chewable/buffered,0.000858841169800173
prostaglandin,0.0008580628748906527
evaluated,0.0008553234328405601
centrally,0.0008523376370749292
might,0.0008486937621018376
myocardium,0.0008481163206235376
particularly,0.0008480954660464723
media,0.0008467885255462049
thus,0.0008459304469449203
inhibition,0.0008427416985996583
levothyroxine,0.000832765758668419
penicillin,0.0008282623561199909
transdermal,0.0008277452424263476
isozyme,0.0008274659561432474
intensify,0.0008230890581847339
inhibitor,0.000822084970764636
total,0.0008207196241515335
non-steroidal,0.0008204209435769272
500,0.0008194726371357763
maleate,0.0008191187232874375
channel,0.0008181968698722786
duration,0.0008163683061862548
sulfate,0.00081467160509896
indicated,0.0008084867001374452
g,0.0008069929182540347
regulate,0.0008057778672905247
themselves,0.0008057778672905247
prostate,0.0008057778672905247
through,0.0008046505621996936
antiarrhythmic,0.0008034903773769253
steady,0.0008029424450015643
multivitamin,0.000802347296264605
metal,0.000802347296264605
its,0.0007997216511088645
potassium-sparing,0.0007991167582809267
catecholamine-depleting,0.0007987416816153114
classes,0.0007986213179465018
myocardial,0.0007984449976203845
combined,0.0007967898917974336
but,0.0007929652299077938
this,0.0007921598023841181
pressure,0.0007919667562651389
subjects,0.0007912653441590756
biloba,0.000790589237169792
sativum,0.000790589237169792
herbs,0.000790589237169792
garlic,0.000790589237169792
allium,0.000790589237169792
initiation,0.0007869912895179798
antineoplastic,0.0007838135528148715
inotropic,0.0007830741627210536
h2,0.0007810984310185898
fold,0.0007806028671384357
hydrocarbon,0.0007793105579556592
halogenated,0.0007793105579556592
divalproex,0.0007773025047983495
15,0.0007766528637501713
toxicity,0.0007754092554205227
enhances,0.0007734755078179223
tears,0.0007731735409641782
hydroxychloroquine,0.0007731735409641782
sj,0.0007731735409641782
grens,0.0007731735409641782
estrogens,0.0007731735409641782
artificial,0.0007731735409641782
14,0.0007705040821870401
initial,0.0007704842874713957
potentiates,0.0007703748510587971
modification,0.0007703748510587971
involving,0.0007695306923590772
esters,0.0007690323552391742
determinant,0.0007690323552391742
antidepressants.when,0.0007674914780931852
irrational,0.0007674914780931852
without,0.0007669895227323531
alkaloids,0.000765850484387931
increasing,0.0007630303382371029
bid,0.0007578590910871652
pharmacodynamics,0.0007565342608013559
then,0.0007553879292087062
40,0.0007545521582685843
formal,0.0007528751166296921
gastric,0.0007468840039088764
convulsions,0.0007450248870739529
desired,0.0007426952515832141
ordinarily,0.0007418240199748016
high,0.0007415850851233419
see,0.0007414175029203385
effective,0.0007412173477799877
liver,0.0007392612963301737
markedly,0.0007389821769052674
amines,0.000734351640257147
nevertheless,0.0007320876888334826
treat,0.0007316815554330169
day,0.0007312943675543693
isosorbide,0.0007309426132915409
altered,0.0007296825464199186
several,0.0007293252327191801
another,0.0007293079228792854
ethinyl,0.000727992392178689
wait,0.0007279066372500864
reduction,0.0007264759123094544
's,0.0007261451032091193
onset,0.0007258915604232419
18,0.0007250682573222145
frequently,0.0007244489959410405
led,0.0007225136090287521
adrenocorticoids,0.0007216937457329431
cortisone-like,0.0007216937457329431
antidepressant,0.0007193281228916604
from,0.0007176798758694591
hydroxide,0.000713211486670029
multivalent,0.0007127490411403814
separate,0.0007124529555653236
experienced,0.0007096749247967882
autonomic,0.0007092948403912835
only,0.0007078014634770424
compared,0.000706877594699229
oxide,0.0007067109254583759
area,0.0007027516941700007
synergistic,0.0007024985195348554
behavior,0.0007024985195348554
non-selective,0.0006992293985237374
primary,0.0006992186350532892
sites,0.0006979688340900125
capsule,0.0006972311324220382
do,0.0006948439383118732
succinate,0.0006920805263166407
iron-containing,0.0006915726221004004
constipation,0.0006909676591630998
augment,0.0006909676591630998
hormones,0.0006899688243398039
200,0.0006896256890949193
displacement,0.0006883088632418932
advisable,0.0006861636959126782
av,0.00068567510981421
curve,0.0006849082356321645
monitor,0.000684836389446053
dyscrasia,0.0006815390203466221
myelotoxicity,0.0006815390203466221
shortness,0.0006815390203466221
killed,0.0006815390203466221
13,0.0006813852478072535
anesthesia,0.0006811802136383882
43,0.0006805197315948863
analyses,0.0006803850004392098
#,0.0006795957144081211
coadministering,0.0006795957144081211
href=,0.0006795957144081211
doxorubicin,0.0006794066776557584
develop,0.0006783462731657641
peak,0.0006771825137179555
species,0.000676418541667001
neurologic,0.0006745497007749623
nephrotoxic,0.0006743771222827988
radiation,0.000673331653484377
change,0.0006728560939897044
breath,0.0006722837993993203
basis,0.0006715008398301414
placebo-controlled,0.0006713853950783832
seizures,0.0006694064682698508
different,0.0006676977507368287
values,0.0006660825062092535
similarly,0.0006654936925937216
chronic,0.0006649082429301956
..,0.0006643436549405024
prostatic,0.0006621824032578827
normal,0.0006618909566395992
anesthetics,0.0006605063984452819
beta-adrenergic-blocking,0.0006596727467454988
importance,0.0006596559705536187
john,0.0006581616430610948
sumatriptan,0.0006567570375869414
constellation,0.0006567570375869414
augmented,0.0006567570375869414
termed,0.0006567570375869414
perhexiline,0.0006557045945143614
stopping,0.000655339664514254
switching,0.000655339664514254
vasodilators,0.0006540394939277272
cough,0.0006540394939277272
115,0.0006540394939277272
sickness,0.0006540394939277272
channel-blocking,0.0006540394939277272
motion,0.0006540394939277272
parentheses,0.0006540394939277272
antigout,0.0006540394939277272
majority,0.0006540394939277272
unless,0.0006538785949163906
contraindications,0.0006538785949163906
depress,0.0006538785949163906
benzodiazepine,0.0006528990145360236
angina,0.0006522508915163261
magnesium-,0.0006507401709969773
cholinergic,0.0006506037580109592
digitalis,0.0006498977923296012
antinociceptive,0.0006495963134789395
supervision,0.0006482076269225256
assessed,0.0006480087239508769
rare,0.000647669608258683
usually,0.0006469350202931157
bound,0.0006465448128559759
predictable,0.0006463070422881856
counteract,0.000642711447076505
live,0.0006424531555658808
vascular,0.0006413711007823286
dopaminergic,0.0006412187089760435
mm,0.0006412187089760435
iib/iiia,0.0006412187089760435
6,0.0006409779779010805
exhibits,0.0006405839510145173
users,0.0006401445384751625
twice,0.000640120962732027
aluminum-containing,0.0006399004262147567
concomitant,0.0006388088695168381
potentially,0.0006356084144854002
bradycardia,0.0006323942167787422
beta-adrenergic,0.0006316991397959937
abnormalities,0.0006310848945296765
25,0.0006300626875528348
medroxyprogesterone,0.0006296795949296552
about,0.0006283145165039139
rate,0.00062680674989124
mycophenolate,0.0006242664728295377
approximate,0.0006233911708442008
side,0.0006232964359016435
prevented,0.000622563930623321
rhabdomyolysis,0.000622563930623321
5-ht1,0.000620519953080656
categories,0.0006199968078102192
22,0.0006174688804752027
higher,0.000617205266812304
catecholamines,0.0006159582505160799
hg,0.0006151226067923066
starting,0.0006099702051144407
thereby,0.0006069696721971996
electrolyte,0.0006068038904625261
discontinues,0.0006056782601007171
initiates,0.0006056782601007171
impair,0.0006045964125854786
qtc,0.000602302351702444
p-450,0.0006015084154157302
bronchospasm,0.0006006287905702123
vaccination,0.0006006287905702123
replication,0.0006006287905702123
interferes,0.0006003461480823535
sensitize,0.0006000982734922777
reverse,0.000599631807446932
particular,0.0005984471106474931
pure,0.0005977387484130681
adversely,0.0005976307356463373
similar,0.0005970784576090349
yogurt,0.0005964408243669395
cheese,0.0005964408243669395
amine,0.0005964408243669395
wine,0.0005964408243669395
window,0.0005964408243669395
bananas,0.0005964408243669395
ripe,0.0005964408243669395
exposures,0.0005957956224218464
anti-inflammatory,0.0005955454838146856
and/or,0.0005952962642682413
influenced,0.0005944976456255802
pk,0.0005944976456255802
mofetil,0.0005944976456255802
example,0.0005939791126917671
0.5,0.0005937794622288273
aluminum,0.0005922148864304644
evaluate,0.0005917136495192654
hypnotics,0.0005916231444237363
thioxanthene,0.0005916231444237363
butyrophenone,0.0005916231444237363
phenothiazines,0.0005916231444237363
nonbarbiturate,0.0005916231444237363
salt,0.0005914106671760511
sustained,0.0005893571271656795
need,0.0005891566584070862
partially,0.0005888036019837672
caused,0.0005885198007951065
1.25,0.0005874630718392115
neurotoxic,0.0005873763206689642
very,0.0005868799944154235
ileus,0.0005868799944154235
prescribed,0.0005865691476243384
produces,0.000584488292503238
cmin,0.0005840171972608665
depresses,0.00058306799661767
tail-flick,0.00058306799661767
content,0.0005820405104852711
nefazadone,0.0005807742589307718
one,0.0005807697701214476
amount,0.0005804319516071743
400,0.0005797467029853287
vaccines,0.000578642207369473
serotonergic,0.0005782525619427714
prolongation,0.0005780560598902529
nitroprusside,0.0005775681156798829
arrhythmias,0.0005749092278669599
profile,0.0005746540901803154
dose-related,0.0005742611420007648
two,0.0005734716092808956
bone,0.0005713483124398788
injectable,0.0005704014893010978
lowered,0.0005703252860020935
discontinuing,0.0005699712856889194
likely,0.0005661994023921091
bromocriptine,0.0005643889932819279
tid,0.0005626519782266914
marrow,0.0005613441745628833
inhibited,0.0005612954051976704
pt,0.000558348730424596
21,0.0005578815945403992
23,0.0005576302682146483
susceptibility,0.0005548123978109665
st,0.0005548123978109665
sulfonylurea,0.0005548123978109665
previous,0.0005542932740792983
tromethamine,0.0005515803254094731
chance,0.0005477280009773544
52,0.0005477280009773544
cardiovascular,0.0005472148648767439
mitogenic,0.0005466485389267195
somatostatin,0.0005448922501706255
sulfonamide,0.0005448922501706255
suppression,0.0005448063407169634
doses,0.0005439305126493377
125,0.0005435162307381169
principal,0.0005425601109407818
ability,0.0005414781720982642
post-marketing,0.0005400466539173809
whose,0.0005398760760068066
reductions,0.0005394995014560422
29,0.0005386651083725269
possibly,0.0005386305270977942
hydrogen,0.0005380512201114129
imipramine,0.00053594544312352
35,0.0005358721526829147
analysis,0.000534972568167813
delirium,0.0005343421916110813
metabolic,0.0005338207841104614
considerably,0.0005337589867490111
antimycotic,0.0005337589867490111
causal,0.000533733040316231
aminoglycoside,0.000533733040316231
vivo,0.0005336438202721006
2-fold,0.0005334092884876629
limited,0.0005327899830160909
contain,0.0005324433904807524
proof,0.0005324433904807524
vitamins,0.0005299432573054874
especially,0.0005289841067773748
elevation,0.0005279559481551344
weeks,0.0005273112376593669
38,0.000527043198248478
whereas,0.0005262309491566031
medical,0.000525036431800574
protein-bound,0.0005236304325940688
displaced,0.0005210920805258645
hormone,0.0005206276076028526
migraine,0.0005198645489901121
maintained,0.0005183566677435802
paralytic,0.0005181652055568087
standing,0.0005180050134148129
systolic,0.0005180050134148129
shorter,0.0005180050134148129
frova_od.htm,0.0005138168630065554
antimycotics,0.0005138168630065554
circulatory,0.0005138168630065554
d2-antagonists,0.0005138168630065554
27,0.0005128829801702706
a.c.,0.0005128829801702706
studied,0.0005095365253973139
careful,0.0005089468993810797
syrup,0.0005077741166121807
versed,0.0005077741166121807
accentuated,0.0005077741166121807
identified,0.0005050889348134913
coadministered,0.0005030345460270702
103,0.0005026288273727308
diabetes,0.0005018331537880449
coumarin,0.0005013620441263189
organ,0.0005001623852571857
antiinflammatory,0.0005001623852571857
pharmacologic,0.0004992292016869904
physicians,0.0004989761588685138
inr,0.0004988517503872192
spontaneous,0.0004987381754681941
depend,0.0004981642584926949
70,0.0004978554659590406
cells,0.0004971988232953528
events,0.0004969744876640592
usual,0.0004968112506325006
alveolar,0.0004964364744647343
begin,0.0004964364744647343
e,0.0004964364744647343
release,0.000495674507091648
male,0.0004955618710578147
permeation,0.0004952984956574369
safety,0.0004946748992601391
given,0.0004946441434644511
displace,0.0004939131661810814
started,0.0004938376684944235
physician,0.0004937761605685598
number,0.0004927192664166968
cardiac,0.0004921476230320687
even,0.0004912727741901435
there,0.0004911618734801948
frequency,0.000489352802022669
efficacy,0.00048687336569686046
completely,0.000486812475037679
ketorolac,0.0004853811411861253
unlikely,0.0004853811411861253
pharmacologically,0.00048421659141806295
contribute,0.0004832928302067607
elevations,0.0004832007451668341
fat,0.0004806119271311138
powder,0.00048058504703585303
antiplatelet,0.0004796049291417859
estrogen/progesterone,0.0004792782015617947
previously,0.00047843091029875495
take,0.0004779023171003205
120,0.0004775468893774004
metabolize,0.00047742754906321405
hypermagnesemia,0.000476996278387376
problems,0.0004768985694796335
however,0.0004767728191557019
characteristics,0.0004757900915879354
exacerbated,0.0004757900915879354
isozymes,0.0004755251066231869
reaction,0.0004751918959430279
rats,0.00047485479840336797
34,0.0004744320116474299
egf-,0.0004727119814241787
toxicities,0.0004727119814241787
alt,0.0004727119814241787
stimulate,0.0004727119814241787
insulin-induced,0.0004727119814241787
irritability,0.0004727119814241787
s.c.,0.0004727119814241787
durations,0.0004727119814241787
lengthened,0.0004727119814241787
brand,0.0004727119814241787
nicotine-induced,0.0004727119814241787
oxytocic,0.0004727119814241787
up,0.0004726451457039982
b-lactam,0.00047014735664951957
pharmacodynamic,0.0004698713475196348
coronary,0.0004691824552047752
thrombocytopenia,0.0004691824552047752
ra,0.0004691824552047752
significance,0.0004690632007917639
eliminated,0.0004671710132660989
products,0.0004663762936072402
incompatible,0.00046570469547657645
prolong,0.00046568551790016066
24-hour,0.000465386505608123
abuse,0.00046527503141402526
level,0.00046485440325327865
bicarbonate,0.0004646518946215261
inhibiting,0.00046436169345898115
trough,0.0004641698518951243
31,0.00046378622230180966
resistance,0.0004626850063772503
seizure,0.0004615366645024377
slight,0.00046100662522197133
hcl,0.00046070264723008236
altering,0.0004600995209786962
mg/kg,0.0004589889892319121
average,0.0004587163206081213
furthermore,0.0004586256714853576
sparing,0.00045707242623549416
database,0.00045563186984654003
herbal,0.00045563186984654003
orally,0.0004542669719324044
qd,0.0004539453683795047
withdrawn,0.0004538451304358926
alkalinizing,0.0004537139645471866
consider,0.0004531693800521319
assess,0.0004522817811417612
1200,0.0004518037259828578
form,0.00045125308328719527
hypokalemia,0.0004509883134663495
neutropenia,0.0004507381138840749
micrograms,0.0004507381138840749
capsules,0.0004493096560204135
experiments,0.00044861087414749257
valproic,0.00044793214015004246
8,0.0004470484910291672
observed,0.0004462794003221582
n=75,0.00044571637661250385
indanavir,0.00044571637661250385
n=72,0.00044571637661250385
n=35,0.00044571637661250385
hiv-protease,0.00044571637661250385
non-thalidomide,0.00044571637661250385
ritanovir,0.00044571637661250385
n=70,0.00044571637661250385
n=79,0.00044571637661250385
n=177,0.00044571637661250385
sympathomimet-ics,0.00044571637661250385
phe-nothiazines,0.00044571637661250385
phenobarbitol,0.00044571637661250385
625,0.00044571637661250385
antiacid,0.00044571637661250385
n=15,0.00044571637661250385
n=21,0.00044571637661250385
n=77,0.00044571637661250385
hemorrhage,0.0004447455011907797
consideration,0.00044421878086908784
slower,0.0004429504065868173
h2-receptor,0.0004428976445838284
fat-soluble,0.0004428976445838284
protein-binding,0.0004428976445838284
history,0.00044208425024561127
occasionally,0.00044119429514255515
antagonist,0.00044119429514255515
soluble,0.000440687938412454
management,0.00044056121018809513
anion-exchange,0.00044056121018809513
resins,0.00044056121018809513
relationship,0.00043972463162011977
ranging,0.0004393112405274291
adjusting,0.00043845455794999655
medicinal,0.0004384545336755252
48,0.00043747454539877495
against,0.0004369241283197489
under,0.0004368334770691318
disturbances,0.00043680616923025273
continue,0.00043680616923025273
adjunctive,0.00043680616923025273
stopped,0.00043680616923025273
photosensitivity,0.0004357772595736664
actinic,0.0004357772595736664
photosensitizing,0.0004357772595736664
h1-blocking,0.0004357772595736664
levulan,0.0004357772595736664
kind,0.0004357772595736664
keratoses,0.0004357772595736664
kerastick,0.0004357772595736664
platelets,0.0004357772595736664
tendency,0.0004357772595736664
suggests,0.0004350249028558517
gluconate,0.0004350249028558517
tnf,0.0004327820016625239
exists,0.0004311583821580145
causes,0.0004306973901729849
molecule,0.00042955436098712774
equivalent,0.00042955436098712774
relevant,0.0004291919259610255
26,0.0004280479893451483
observations,0.000426635301304934
gold,0.0004257989676852425
methylergonovine,0.0004257989676852425
pulse,0.0004257989676852425
ssri,0.0004257989676852425
combining,0.0004257989676852425
obstipation,0.0004257989676852425
appropriately,0.0004257989676852425
better,0.0004257989676852425
phosphorylation,0.0004250209943921224
tissue,0.0004250209943921224
presumably,0.00042471968999269194
7.5,0.0004246519812347582
glycosides,0.0004242642705886146
risks,0.00042423369295097046
folate,0.00042408560125073436
colitis,0.00042408560125073436
crohns,0.00042408560125073436
sugar,0.00042408560125073436
ulcerative,0.00042408560125073436
inflammation,0.00042408560125073436
utilization,0.00042408560125073436
concern,0.00042408560125073436
mcg,0.0004227484689088845
topical,0.00042274091987115625
attenuates,0.00042268564701053446
cross-resistance,0.00042268564701053446
analgesia,0.00042268564701053446
susceptible,0.00042268564701053446
cyp2b6,0.0004218051715736415
minor,0.00042121897405023034
animal,0.0004208088813223432
contractility,0.00041954122277776396
life-threatening,0.00041923595889914456
tpmt,0.00041866328747897086
reciprocal,0.00041866328747897086
aminosalicylate,0.00041866328747897086
foods,0.00041545810958221185
bacteriostatic,0.0004144759247268759
contraceptives,0.0004135854887892254
therapies,0.0004135854887892254
regression,0.000413430115177027
19,0.000413430115177027
fruit,0.000413430115177027
ascorbic,0.000413430115177027
juices,0.000413430115177027
glutamic,0.000413430115177027
apparent,0.000413430115177027
substantially,0.0004129474197676064
periodic,0.0004110342147591872
quinolone,0.0004099421604677467
elderly,0.0004084075232404505
threshold,0.000408407272375233
prior,0.0004082532329994226
solution,0.0004082074113218592
vary,0.00040605905523716235
d3,0.00040594353794354276
receptor,0.0004048384881520928
x,0.00040446523674031454
render,0.0004030386549498388
pediatric,0.00040196592643115814
myelotoxic,0.00040189110146260365
oxide/oxygen,0.00040189110146260365
cardiotoxic,0.00040189110146260365
possessing,0.00040189110146260365
3-fold,0.00040104035396115734
anesthetic,0.00039987879327618714
reduces,0.00039861180342248836
extended,0.00039827082020726934
minutes,0.0003980583334283194
thereafter,0.00039695364478986583
supraventricular,0.00039695364478986583
ototoxicity,0.00039695364478986583
included,0.00039614588756531344
alternative,0.00039560807979688306
urine,0.0003954150332678985
unpredictable,0.0003947266154844531
family,0.0003946703720615341
ingested,0.0003940640383547356
loss,0.00039393479472560333
parent,0.00039389700724212773
discontinuation,0.00039283944166590423
crisis,0.00039114174574195193
hyperthermia,0.00039114174574195193
sedative/hypnotics,0.0003909506035272292
elevating,0.00038928628802059606
demonstrates,0.00038928628802059606
blunting,0.00038786197284312873
stimulated,0.00038786197284312873
-8,0.00038786197284312873
beta-adrenoceptor,0.00038786197284312873
rise,0.00038786197284312873
states,0.00038786197284312873
rigidity,0.00038786197284312873
protection,0.00038786197284312873
exaggerate,0.00038786197284312873
sgpt,0.00038786197284312873
hypoglycemia,0.00038730923058838407
anticonvulsant,0.0003871551723847455
b12,0.00038654788196734735
affinity,0.00038623318487474023
octapeptide,0.00038623318487474023
cholecystokinin,0.00038623318487474023
moieties,0.00038623318487474023
three,0.00038567010309520366
bretylium,0.0003849035503463716
tosylate,0.0003849035503463716
44,0.00038482117907867597
co,0.000384631440870864
hypertensive,0.00038406884096064964
recently,0.00038406884096064964
chelation,0.0003840653463179633
shortened,0.0003838278226463432
eproxindine,0.0003832794351005253
mice,0.00038249429053260897
although,0.0003824517615353962
33,0.00038184270285968047
pth,0.0003817591261137121
frequent,0.0003817591261137121
simultaneous,0.0003816917781345186
95,0.00038141436977690013
addition,0.00038135922536697286
reductase,0.0003812676110324098
800,0.0003804849141570976
model,0.00037910389299267155
tablet,0.0003790236627401189
unchanged,0.0003790236627401189
hypercalcemia,0.00037880478675544893
meaningful,0.0003771201349380693
divalent,0.0003768213558914546
trivalent,0.0003768213558914546
atropine,0.0003763632237894221
diphenoxylate,0.0003763632237894221
peptide,0.00037632094712169994
safely,0.00037632094712169994
complexes,0.00037610850854619127
formulations,0.00037610850854619127
tract,0.00037567548440597953
population,0.00037516637147883003
exert,0.0003749224138267504
benefits,0.0003749224138267504
parenteral,0.00037332484953178646
0.25,0.00037221770808704147
tachycardia,0.00037135315281389136
leading,0.0003713424097573359
iiia4,0.0003709554999731246
600,0.00037051688352174317
degree,0.00036965361741669867
concentration-time,0.00036767453936503713
hypokalemic,0.0003675832238428933
diphenhydramine,0.0003675832238428933
inotropes,0.0003675832238428933
potassium-containing,0.0003675832238428933
substitutes,0.0003675832238428933
gp,0.0003675832238428933
longer,0.0003675089993642189
carbonate,0.0003674166855284211
amitriptyline,0.0003664153462348274
incompatibility,0.0003664091742621167
profiles,0.0003656624683601173
100,0.0003651500238150973
ci,0.00036453480633524826
cyp1a2,0.00036090271005440044
contraception,0.000360167055082794
stimulants,0.000360167055082794
enhancement,0.0003589793289058285
cyclosporine,0.00035832542559099956
bactericidal,0.00035814695645963734
hyperkalemia,0.0003577059718662401
outweigh,0.00035763005050004626
downward,0.00035763005050004626
cortex,0.00035649786625302493
pharmacist,0.00035649786625302493
ampicillin/flucoxacillin,0.00035649786625302493
mic,0.00035649786625302493
subcortical,0.00035649786625302493
white,0.00035649786625302493
frontal,0.00035649786625302493
pharmacokinetics/pharmacodynamics,0.00035649786625302493
forebrain,0.00035649786625302493
structures,0.00035649786625302493
nonprescription,0.00035649786625302493
dialysis,0.00035634983429078115
4-fold,0.0003556471827832475
injection,0.0003553342595468134
developing,0.0003550586070213413
accumbens,0.0003550586070213413
tnf-blocking,0.0003550586070213413
non-,0.0003550586070213413
nucleus,0.0003550586070213413
para-aminosalicylic,0.0003544765004318551
ed50,0.0003544765004318551
fresh,0.0003544765004318551
heavy,0.0003544765004318551
therapeutically,0.0003544765004318551
plasmaconcentration,0.0003544765004318551
triazolo-benzodiazepines,0.0003544765004318551
phosphate,0.0003544765004318551
ionized,0.0003544765004318551
ammonium,0.0003544765004318551
lasting,0.0003544765004318551
p450iiia4,0.0003544765004318551
malabsorption,0.0003544765004318551
biotransformation,0.0003544765004318551
hospitalization,0.0003531829099612249
antagonists,0.0003525978372708183
signs,0.0003514901280596838
inhaled,0.00035094705118010605
small,0.0003507731680193471
report,0.00035063000476054373
determined,0.00035055578262244147
obtained,0.00034951703628327557
=,0.0003495061496380236
minimized,0.000349471134961421
85,0.00034902875941267286
anticoagulant,0.0003483926687222194
salicylate,0.00034799062598189767
genentech,0.00034741031627549823
alfa,0.00034741031627549823
-agonists,0.00034741031627549823
anti-pseudomonal,0.00034741031627549823
dornase,0.00034741031627549823
noted,0.00034741031627549823
whole,0.00034741031627549823
complete,0.00034704088554304846
purpose,0.0003465870230503487
groups,0.00034641663191048444
analogues,0.00034628553085302993
mechanism,0.00034574855010682803
digestive,0.0003454076346605106
adsorbents,0.0003454076346605106
carbohydrate-splitting,0.0003454076346605106
1.4-,0.0003454076346605106
elc,0.0003454076346605106
1.6-,0.0003454076346605106
2.9-,0.0003454076346605106
2.0-,0.0003454076346605106
ewes,0.0003454031309066963
believed,0.0003454031309066963
hiv-positive,0.0003454031309066963
hypoparathyroid,0.0003454031309066963
contained,0.0003454031309066963
pregnancies,0.0003454031309066963
thiosulfate,0.0003454031309066963
hyperuricemic,0.0003454031309066963
-5,0.0003454031309066963
ectopic,0.0003454031309066963
alpha-adrenergic,0.0003454031309066963
ast,0.0003454031309066963
attributed,0.0003454031309066963
109/l,0.0003454031309066963
crises,0.0003454031309066963
prevents,0.0003454031309066963
anc,0.0003454031309066963
food,0.0003453282471910235
pump,0.00034448055579150427
proton,0.00034448055579150427
hmg-coa,0.000344070191785395
gradual,0.0003438349533844143
e.g,0.0003435929853333741
involved,0.00034234312210779105
administrations,0.0003420791524884059
maximum,0.0003416002279337249
anticoagulation,0.00034111541132819667
after,0.00034092042069877593
specifically,0.00034055894102247297
norepinephrine,0.00034055894102247297
pretreatment,0.00034029737601859456
lowering,0.00034022032668989954
epilepsy,0.0003399471832690182
large,0.00033987160310877673
we,0.0003372756881621086
greater,0.0003369068893905869
transient,0.00033673496182018425
reversible,0.00033673496182018425
minimally,0.00033668420154864265
pose,0.0003358599705507448
additionally,0.00033545875058360597
achieve,0.00033461575190874004
-nanm,0.0003345150205258385
requires,0.000333869410425347
their,0.0003337750114011939
oxidation,0.0003334155972885
over-,0.0003332277504034531
under-digitalization,0.0003332277504034531
elevate,0.0003328767814825273
coumarin-like,0.00033215614017911843
where,0.00033194888405030376
1000,0.00033141996304597576
infections,0.00033123386448707937
responsiveness,0.0003308242499163727
postmarketing,0.0003308242499163727
iodide,0.0003308242499163727
structural,0.0003308242499163727
organophosphate,0.0003308242499163727
phospholine,0.0003308242499163727
carbamate,0.0003308242499163727
odds,0.0003308242499163727
1.11-2.38,0.0003308242499163727
1.02-2.11,0.0003308242499163727
antimuscarinic,0.0003308242499163727
antiparkinson,0.0003308242499163727
weaken,0.0003308242499163727
1.27-2.12,0.0003308242499163727
1.64,0.0003308242499163727
1.73,0.0003308242499163727
steroidal,0.0003308242499163727
1.47,0.0003308242499163727
1.63,0.0003308242499163727
1.25-2.38,0.0003308242499163727
ssri-tca,0.000330781884592124
sequential,0.000330372252865474
minimum,0.000330372252865474
mac,0.00032956346480483845
morphine-induced,0.00032946691530710837
class,0.00032883113163184596
curves,0.0003282120466506777
aggregation,0.0003282120466506777
diarrhea,0.0003282120466506777
kip1,0.0003282120466506777
manner,0.0003282120466506777
p27,0.0003282120466506777
arrhythmia,0.00032804501553806986
ototoxic,0.00032804501553806986
warned,0.00032768348466682973
advice,0.00032768348466682973
act,0.00032768348466682973
inhaler,0.00032768348466682973
start,0.00032768348466682973
cisplatin.1,0.00032768348466682973
metaproterenol,0.00032768348466682973
vertigo,0.00032768348466682973
cremophor,0.00032768348466682973
concentrate,0.00032768348466682973
el,0.00032768348466682973
533/133,0.00032768348466682973
isrecommended,0.00032768348466682973
surgical,0.00032768348466682973
nortriptyline,0.00032768348466682973
wyeth-ayerst,0.00032768348466682973
28,0.0003268018338541401
requirements,0.0003264436307546248
eight-fold,0.0003256311775364784
motility,0.0003253793282771422
magnesium-containing,0.0003251335508025477
titration,0.00032376578202375494
prescribing,0.00032376578202375494
240,0.0003229732422131981
conclusions,0.0003229732422131981
cases,0.00032206535448175977
nephrotoxicity,0.000321730154398292
chemotherapy,0.00032167003134919714
while,0.00032129528572566457
established,0.0003198351863383797
regimens,0.00031900994083366996
metabolites,0.00031817938207190366
54,0.00031767508705571323
ratio,0.00031706654831931136
differences,0.0003168572818443849
isoenzymes,0.0003165400759364001
microsomal,0.00031567605384963393
severity,0.000315116221397016
antagonistic,0.000315116221397016
multiple-dose,0.000314462837897711
early,0.0003144422684772108
imidazole,0.0003144422684772108
m,0.0003137853092747278
co-medications,0.0003132536968476485
stabilized,0.00031279174440246305
c.p.a,0.00031279174440246305
corresponding,0.00031264717387313734
poorly,0.00031264717387313734
remedies,0.00031264717387313734
neurons,0.0003107835474782661
insecticides,0.0003107835474782661
cyp2c19,0.0003107587883497409
transplant,0.0003106164068562567
intracellular,0.0003104366588604357
anaesthetised,0.00031011327433572156
2-,0.0003096130706558009
41,0.0003096130706558009
whether,0.0003087168395417006
formulation,0.0003079830212932011
racemic,0.0003073611136199528
converting,0.00030724288406747124
72,0.00030716002748132354
brain,0.0003069599016153335
numerous,0.00030694829743060925
deficiency,0.00030694829743060925
suffering,0.00030463781735623474
special,0.00030463781735623474
insufficient,0.00030463781735623474
minipill,0.00030463781735623474
individual,0.00030463781735623474
smaller,0.00030463781735623474
current,0.00030463781735623474
vasospastic,0.00030463781735623474
microdosed,0.00030463781735623474
hormonal,0.000304494312861725
enhancing,0.00030436218335871956
appears,0.00030432958151871414
animals,0.00030432958151871414
calcitriol/ergocalcitriol,0.0003043007698700917
ventricular,0.00030361130403433467
anti-infective,0.0003035857899568173
please,0.0003035857899568173
ecg,0.0003035857899568173
irreversibly,0.0003035857899568173
simultaneously,0.00030275398086776484
responsible,0.00030184323047921513
accelerating,0.0003017358242946022
phenytoin/phenobarbital,0.0003017358242946022
employed,0.0003014814889782391
salicylic,0.00030092288224492503
recovery,0.0003009225716082975
tests,0.00030090393531900794
b.i.d,0.00030035784970827706
angiotensin,0.0002997448333077468
ml,0.00029764576515756147
effectively,0.00029703977760509037
36,0.00029636683511202744
suggested,0.0002961426993266514
would,0.000295002878972106
exacerbate,0.00029400366529719335
great,0.00029400366529719335
6-fold,0.00029359553011854
moderate,0.0002917880675421536
indicate,0.0002917347583473173
breast,0.00029117911108866856
nor,0.0002908630427579384
few,0.000290262918874018
steroid,0.0002893437625167694
17,0.0002890461319307036
dextromethorphan,0.0002886245087276862
n-acetyltransferase,0.0002886245087276862
rebound,0.0002886245087276862
porpranolol,0.0002886245087276862
potassium-,0.0002886245087276862
donor,0.0002886245087276862
agitation,0.0002886245087276862
hydrobromide,0.0002886245087276862
dipotassium,0.0002886245087276862
anti-malarial,0.0002886245087276862
beta-blockers,0.0002886245087276862
nitric,0.0002886245087276862
suppress,0.0002886245087276862
noncardioselective,0.0002886245087276862
ptca/pci,0.0002886245087276862
clorazepate,0.0002886245087276862
glycoprotein,0.0002886245087276862
methemoglobinemia,0.0002886245087276862
demonstrated,0.00028835024351447913
information,0.0002882357866835772
implications,0.00028727954712681747
anecdotal,0.00028727954712681747
phentermine,0.00028727954712681747
bovine,0.00028713172232397444
quantities,0.00028713172232397444
phenytoin,0.00028713172232397444
unknown,0.00028636133835258093
mineral,0.00028630758324676986
3-4,0.00028630758324676986
ss,0.00028630758324676986
oil,0.00028630758324676986
55,0.00028630758324676986
note,0.0002861726677012566
tested,0.0002860326526492596
drug/laboratory,0.0002841034638387807
findings,0.00028378396076367274
laboratories,0.00028378396076367274
lopinavir/ritonavir,0.00028378396076367274
changing,0.00028378396076367274
ganglion,0.00028378396076367274
according,0.00028378396076367274
reason,0.00028378396076367274
cell,0.00028372102752216577
appear,0.0002835386207780122
"2-methyl-1,3-thiazol-4-yl",0.00028183392055813883
sensitivity,0.00028183392055813883
nasal,0.0002813048708749655
proteins,0.00028098274936350087
organic,0.0002808920689764127
fluoxetine,0.00028016360345706204
net,0.00028016360345706204
valproate,0.00028016360345706204
modifies,0.00028016360345706204
non-ionized,0.00028016360345706204
carbenicillin,0.00028016360345706204
indanyl,0.00028016360345706204
vaiproic,0.00028016360345706204
indigestion,0.00028016360345706204
intense,0.00028016360345706204
calan,0.00028016360345706204
sr,0.00028016360345706204
2.93-fold,0.00028016360345706204
13.3-fold,0.00028016360345706204
1.5-2.5,0.00028016360345706204
q12h,0.00028016360345706204
modify,0.00027983550180232797
rpmi1640,0.00027983550180232797
compounds,0.00027913211614527533
impaired,0.0002781709836247037
fluorescein,0.0002772241315436297
iodine-containing,0.0002772241315436297
conjugates,0.0002772241315436297
chains,0.0002772241315436297
n-methylthiotetrazole,0.0002772241315436297
quart,0.0002772241315436297
sulfamethoxazole-trimethoprim,0.0002772241315436297
cephalosporins-cephalosporins,0.0002772241315436297
carboxymethylcellulose,0.0002772241315436297
7-10/interaction,0.0002772241315436297
nyha,0.0002772241315436297
candesartan,0.0002772241315436297
cilexetil,0.0002772241315436297
methylthiadiazole,0.0002772241315436297
sulfa-based,0.0002772241315436297
andtolbutamide,0.0002772241315436297
sheep,0.0002772241315436297
anticoagulants,0.0002761542083493662
intraventricular,0.00027497685385835524
ethynyl,0.00027497685385835524
beta-blocking,0.00027363739857189096
parameters,0.0002730166820277269
striking,0.0002725124861311379
16,0.0002710305701962845
11,0.00027085134738558114
mg/kg/day,0.0002702403968350975
here,0.00027022731850523396
slightly,0.0002700701305401454
heart,0.0002695133140961925
chronically,0.00026874898333295594
ii,0.0002685321016656639
conjunction,0.0002679013701750721
low,0.0002678604425793152
experiences,0.00026780814522064933
stimulation,0.0002673615392002615
5-ht3,0.00026731700522053536
failure,0.00026716315989505635
endogenous,0.00026605912731203496
theoretically,0.00026585860005479134
exceeded,0.00026548686725569315
less,0.0002646317362301476
vessels,0.00026443502261797036
placental,0.00026443502261797036
laboratory,0.0002638817263901361
adequate,0.00026385850782095766
blocks,0.00026375192865035757
replacement,0.0002624388668541755
hypoprothrombinemia,0.00026159755866450585
iii,0.00026112186605931065
malignant,0.0002609295909674625
changes,0.00026080381476589753
also,0.00026037664823863604
currently,0.00026021219517435856
epileptic,0.0002601520170656402
locomotor,0.0002597791858323095
consequences,0.0002597791858323095
fibrillation,0.0002597791858323095
ip,0.0002597791858323095
made,0.000258854997494784
phase,0.00025826789565619457
psychoactive,0.00025756859709791247
reversed,0.00025756859709791247
labeling,0.0002574103433109487
chromaffin,0.0002574103433109487
intravenously,0.0002571498768466629
clotting,0.0002567485393840663
alternatives,0.0002567485393840663
regardless,0.0002567485393840663
rates,0.0002567485393840663
toxic,0.00025639257578158325
added,0.00025598682174310383
percent,0.00025581343345448815
inflammatory,0.00025479234228453773
undergoing,0.0002545128296346233
plus,0.0002544336370718936
competitively,0.00025299724768079734
controlled,0.0002527158015286357
competes,0.0002524433147703675
insufficiency,0.0002510583848340797
concluded,0.0002488451639861555
similarity,0.0002488451639861555
cerebral,0.0002488451639861555
those,0.0002485850718416671
1.5,0.00024750414577145996
omega-conotoxin,0.00024750414577145996
omega-agatoxin,0.00024750414577145996
n-type,0.00024750414577145996
p-type,0.00024750414577145996
metabolizers,0.0002467390350402443
major,0.00024577293996719263
53,0.0002452176086830127
39,0.0002452176086830127
two-fold,0.0002452176086830127
anticholinesterase,0.00024462759598697925
lead,0.00024458488223921826
case,0.0002445367490957473
males,0.00024329379326659684
prescription,0.000242557534965826
ganglionic,0.00024142411606897785
solutions,0.00024142411606897785
mouse,0.00024020123568935237
2.5,0.00024012392719996445
5-fold,0.0002394363210963535
compete,0.0002394363210963535
twofold,0.0002394363210963535
12,0.00023938058964456665
directly,0.00023917832905318015
body,0.00023847525938258674
judgment,0.00023834201297945334
functioning,0.00023834201297945334
vasodilator,0.00023834201297945334
acidity,0.00023834201297945334
plasmaconcentrations,0.00023834201297945334
becausedecreases,0.00023834201297945334
dantrolene,0.00023834201297945334
potassium-depleting,0.00023834201297945334
beadministered,0.00023834201297945334
curare-like,0.00023834201297945334
interfering,0.00023834201297945334
blocked,0.0002377479548693051
developed,0.0002377479548693051
apnea,0.0002377479548693051
gravis,0.0002377479548693051
myasthenia,0.0002377479548693051
8-2698,0.0002377479548693051
antibody,0.0002377479548693051
adl,0.0002377479548693051
carried,0.00023759841255777125
monotherapy,0.00023759841255777125
g/ml,0.0002371147955042563
3900,0.0002371147955042563
renin,0.0002366722271691657
prevent,0.00023655163525504452
all,0.00023634283074425166
augments,0.00023628044634316225
-9,0.00023628044634316225
non-depolarising,0.00023628044634316225
parental,0.00023628044634316225
p3,0.00023628044634316225
immunosuppressive,0.00023628044634316225
-10,0.00023628044634316225
necessitated,0.00023628044634316225
0.3,0.00023628044634316225
-7,0.00023628044634316225
parts,0.00023628044634316225
p1,0.00023628044634316225
continuously,0.00023628044634316225
kill,0.00023628044634316225
diminishes,0.00023628044634316225
microm,0.00023628044634316225
bacilli,0.00023628044634316225
beta-lactam,0.00023628044634316225
-6,0.00023628044634316225
partly,0.00023628044634316225
cypermethrin-induced,0.00023628044634316225
sodation,0.00023628044634316225
mumol/liter,0.00023628044634316225
ig,0.00023628044634316225
4th,0.00023628044634316225
vasoconstricting,0.00023628044634316225
levamisole,0.00023628044634316225
fall,0.00023628044634316225
bcl-2,0.00023628044634316225
blunted,0.00023628044634316225
epidemiological,0.00023628044634316225
attenuated,0.00023628044634316225
equally,0.00023628044634316225
cephalosporin,0.00023628044634316225
status,0.00023628044634316225
confusional,0.00023628044634316225
aware,0.00023628044634316225
aav2-mediated,0.00023628044634316225
myeloproliferative,0.00023628044634316225
tnfa-blocking,0.00023628044634316225
fluctuations,0.00023628044634316225
progressing,0.00023628044634316225
instability,0.00023628044634316225
myoclonus,0.00023628044634316225
prolactin,0.00023628044634316225
depression-producing,0.00023628044634316225
peroxidation,0.00023628044634316225
n1,0.00023628044634316225
radical-mediated,0.00023628044634316225
tbars,0.00023628044634316225
antabuse-like,0.00023628044634316225
retention,0.00023628044634316225
cdk1,0.00023628044634316225
trazodone,0.00023628044634316225
renin-angiotensin,0.00023628044634316225
anti-glaucoma,0.00023628044634316225
688,0.00023626407955401607
subtherapeutic,0.00023626407955401607
10-20,0.00023626407955401607
nonabsorbable,0.00023626407955401607
co-treatment,0.00023626407955401607
beneficial,0.00023618361844390812
high-dose,0.00023618361844390812
capable,0.00023529989964288234
coagulation,0.0002349635592067134
clomipramine,0.0002348736537435281
decreasing,0.0002348736537435281
accumulation,0.0002348736537435281
terminal,0.00023441736179208306
show,0.00023438085624405414
add,0.0002324648466995871
place,0.00023208426807208582
ischemic,0.00023208426807208582
adult,0.000232009156770685
n,0.00023139955844553306
strongly,0.00023135314165312337
t1/2,0.00023135314165312337
ingestion,0.00023060244016481768
four,0.0002305148434080806
fever,0.0002304496865984662
trial,0.00023015363291145619
adults,0.0002299143450175123
-induced,0.0002298360494932261
provided,0.00022921331179615034
hypersensitivity,0.0002289607840342267
regimen,0.0002282810635607646
t.i.d,0.00022816026181482485
disposition,0.00022769314362691695
indicating,0.00022769314362691695
months,0.00022769314362691695
suspension,0.00022677799423709288
difference,0.0002262541259590023
includes,0.0002262541259590023
2.2-fold,0.0002258031020122564
1.7-fold,0.0002258031020122564
im,0.00022576609548963233
category,0.00022576609548963233
bind,0.00022576609548963233
nonetheless,0.00022524755578512412
giving,0.00022524755578512412
transmission,0.00022524755578512412
systems,0.0002247133940029844
peripheral,0.00022457288337074388
vasoconstrictive,0.0002241629443523463
affected,0.0002239752671071571
alter,0.0002230710196592378
they,0.00022192507308560483
blockers/proton,0.00022177403309331378
antituberculosis,0.00022177403309331378
low-dose,0.00022177403309331378
emerge,0.00022045559154260097
amounts,0.00022045559154260097
diuretic-induced,0.00022045559154260097
interleukin-1,0.00022045559154260097
1.2,0.00022045559154260097
deterioration,0.00022045559154260097
tumor,0.0002199543505359003
3-,0.00021910873635144767
normalized,0.00021900571919242218
confusion,0.00021883318233606452
occurrence,0.00021883318233606452
allowed,0.00021835965730165885
tachypnea,0.00021835965730165885
checked,0.00021835965730165885
travelers,0.00021835965730165885
departure,0.00021835965730165885
comedication,0.00021835965730165885
sole,0.00021835965730165885
anorexia,0.00021835965730165885
insure,0.00021835965730165885
inwomen,0.00021835965730165885
back-up,0.00021835965730165885
2-week,0.00021835965730165885
usedas,0.00021835965730165885
pre-existing,0.00021835965730165885
initiate,0.00021835965730165885
hormonalmethods,0.00021835965730165885
thesemedications,0.00021835965730165885
parenterally,0.00021835965730165885
depletors,0.00021835965730165885
compensatory,0.00021835965730165885
pcp,0.00021835965730165885
upward,0.00021835965730165885
lethargy,0.00021835965730165885
carbonic,0.00021835965730165885
anhydrase,0.00021835965730165885
prudent,0.00021835965730165885
professional,0.00021835965730165885
know,0.00021835965730165885
consumption,0.00021835965730165885
bupropz_od.htm,0.00021835965730165885
ensure,0.00021835965730165885
assure,0.00021835965730165885
immunomodulating,0.00021835965730165885
conservatively,0.00021835965730165885
weighed,0.00021835965730165885
thrombus,0.00021835965730165885
hyperlipidemia,0.00021835965730165885
tcatreatment,0.00021835965730165885
still,0.00021835965730165885
leprosy-associated,0.00021835965730165885
selecting,0.00021835965730165885
cautious,0.00021835965730165885
finding,0.00021835965730165885
essential,0.00021835965730165885
timing,0.00021835965730165885
releases,0.00021835965730165885
intestines,0.00021835965730165885
72-hour,0.00021835965730165885
oxi-dase,0.00021835965730165885
intranasal,0.00021835965730165885
beta-blockade,0.00021835965730165885
dictates,0.00021835965730165885
interrupted,0.00021835965730165885
syncope/presyncope,0.00021835965730165885
ipth,0.00021835965730165885
definitely,0.00021835965730165885
myasthenic,0.00021835965730165885
routine,0.00021835965730165885
deferred,0.00021835965730165885
awareness,0.00021835965730165885
nevirapinemay,0.00021835965730165885
bear,0.00021835965730165885
precautions,0.00021835965730165885
warfarin-type,0.00021835965730165885
5-mg,0.00021835965730165885
t.a,0.00021835965730165885
out,0.00021818025610320646
acei/arb,0.0002177883389349322
baseline,0.0002177883389349322
common,0.000217326515018601
dyspnea,0.00021652314579623244
vasospasm,0.00021652314579623244
monkeys,0.00021646173230738253
aluminum-,0.00021624160982225415
non-potassium,0.0002161429160059125
except,0.0002161429160059125
immediate,0.00021592730377639757
procedures,0.00021576890482044586
half-lives,0.00021576890482044586
45,0.00021574558070081018
sympathetic,0.00021520480436165723
lipid,0.00021520480436165723
woman,0.00021520480436165723
co-administered,0.00021518492904482045
creatinine,0.00021474241941277228
gland,0.00021469317712041747
coumarin-type,0.00021439248581323067
every,0.00021407767745484918
likelihood,0.00021340970975780582
300-600,0.00021316642232438454
one-fourth,0.00021316642232438454
responses,0.00021282439586300939
progestin-only,0.00021251881214578994
suggesting,0.00021109671495533888
horses,0.00021077090405174914
f2alpha,0.00021077090405174914
five,0.00021064614637322787
association,0.0002103543584102141
weight,0.0002103543584102141
peritoneal,0.0002101624235539834
suitable,0.0002100530371090814
prostaglandins,0.0002096681745969997
2/3,0.00020922865817452063
cyp450,0.00020922865817452063
histamine,0.00020904988963676985
sudden,0.00020891580148330036
receive,0.00020891580148330036
relevance,0.00020891580148330036
well-controlled,0.00020840291548740453
resin,0.00020821140761717594
90,0.000208047471937034
post-myocardial,0.0002078839984387404
vehicle,0.0002078839984387404
crohn,0.0002078839984387404
162.5,0.0002078839984387404
activities,0.0002078839984387404
m/v,0.0002078839984387404
aspirin/acetaminophen,0.0002078839984387404
premedications,0.0002078839984387404
channels,0.0002078839984387404
g/kg/min,0.0002078839984387404
antiemetics,0.0002078839984387404
screening,0.0002078839984387404
uniformity,0.0002078839984387404
sali-cylates,0.0002078839984387404
variety,0.0002078839984387404
ephesus,0.0002078839984387404
3020,0.0002078839984387404
91,0.0002078839984387404
measurement,0.0002078839984387404
40-mg,0.0002078839984387404
meq,0.0002078839984387404
n=8,0.0002078839984387404
antagonism,0.00020740588074974475
vasodilation,0.00020666049442708
sporadic,0.00020666049442708
worsened,0.00020666049442708
instituted,0.00020666049442708
acutely,0.00020666049442708
indirect-acting,0.00020666049442708
weekly,0.0002059503645536198
dihydropyridine,0.00020536861031639209
first,0.0002041168203058552
estrogen-containing,0.00020405794167854818
aerosol,0.00020405794167854818
play,0.00020405794167854818
hypervitaminosis,0.00020405794167854818
isomer,0.00020405794167854818
self-administration,0.00020375304901576463
relative,0.00020287709872290893
though,0.00020236993239242107
neither,0.0002022997470205734
requirement,0.00020173413302448928
p,0.00020165351414891397
300,0.00020155170474089878
antitumor,0.0002010930919972287
lowest,0.00020076865249885056
d2,0.0002002734716290977
benefit,0.00019936303382472875
hepatotoxicity,0.00019936303382472875
larger,0.00019874540367259552
irritation,0.0001983016134319282
aminosalicylates,0.00019798012209426563
regarding,0.0001977657665801491
hemostasis,0.00019766135976373445
complex,0.00019702605426863418
+,0.00019688610238044468
exhibited,0.00019555702929974217
twitch,0.00019555702929974217
flushing,0.00019555702929974217
rat,0.00019528972453852766
mucosa,0.00019461390892194785
dsm-iv-diagnosed,0.00019461390892194785
bipolar,0.00019461390892194785
enzyme-inducer,0.00019461390892194785
describes,0.00019461390892194785
accelerated,0.00019461390892194785
gm,0.00019461390892194785
350,0.00019461390892194785
discussion,0.00019461390892194785
arise,0.00019461390892194785
cationic,0.00019461390892194785
3.6,0.00019461390892194785
marker,0.00019461390892194785
plasma-level,0.00019461390892194785
aucs,0.00019461390892194785
glutathione-s-transferase,0.00019461390892194785
sharing,0.00019461390892194785
extends,0.00019461390892194785
anion,0.00019461390892194785
2002,0.00019461390892194785
dissolving,0.00019461390892194785
chloride-induced,0.00019461390892194785
lesions,0.00019461390892194785
chicks,0.00019461390892194785
wax,0.00019461390892194785
permits,0.00019461390892194785
firmly,0.00019461390892194785
abnormal,0.00019461390892194785
tubularly,0.00019461390892194785
secreted,0.00019461390892194785
rachitic,0.00019461390892194785
reddish,0.00019461390892194785
dehydrogenase,0.00019461390892194785
displaces,0.00019461390892194785
coat-core,0.00019461390892194785
1.6-g,0.00019461390892194785
anionic-binding,0.00019461390892194785
pre-treatment,0.00019461390892194785
17-28,0.00019461390892194785
raise,0.00019461390892194785
serosal,0.00019461390892194785
ultimate,0.00019461390892194785
cimetidine,0.00019461390892194785
turn,0.00019461390892194785
calcium-rich,0.00019461390892194785
56,0.00019461390892194785
5-6,0.00019461390892194785
accelerates,0.00019461390892194785
99m-tco-4-injection,0.00019461390892194785
accumulated,0.00019461390892194785
195,0.00019461390892194785
mg/week,0.00019461390892194785
845,0.00019461390892194785
mg/d,0.00019461390892194785
648,0.00019461390892194785
variation,0.00019461390892194785
ingesting,0.00019461390892194785
deleted,0.00019461390892194785
higher-than,0.00019461390892194785
separating,0.00019461390892194785
minimizes,0.00019461390892194785
equivocally,0.00019461390892194785
400-mg,0.00019461390892194785
p-450iie1,0.00019461390892194785
fluctuate,0.00019461390892194785
cime-tidine,0.00019461390892194785
tcametabolism,0.00019461390892194785
leukopenic,0.00019461390892194785
isoform,0.00019461390892194785
indices,0.00019461390892194785
56.9,0.00019461390892194785
standard,0.00019421617720549733
long-term,0.00019420948425308282
substantial,0.0001931406813988623
potentiation,0.00019313693124445308
pivoxil,0.00019298539332490705
n=6,0.00019298072198703498
1.7-gram,0.00019298072198703498
500-mg,0.00019298072198703498
g/kg,0.00019246429148678246
design,0.0001923809224402273
case-control,0.0001923809224402273
locus,0.0001923809224402273
noradrenaline,0.0001923809224402273
oxidative,0.0001923809224402273
exacerbation,0.0001923809224402273
embryos,0.0001923809224402273
expression,0.0001923809224402273
p2,0.0001923809224402273
co-injection,0.0001923809224402273
cytotoxicity,0.0001923809224402273
elemental,0.00019231679140174762
components,0.00019150972571280178
transit,0.0001914590559818352
glucose,0.00019116834197330235
potently,0.00019082213176979668
mediated,0.00019082213176979668
undetectable,0.00019082213176979668
145mg,0.00019082213176979668
phosphorylated,0.00019082213176979668
261,0.00019082213176979668
128,0.00019082213176979668
sustained-release,0.00019082213176979668
67,0.00019082213176979668
145,0.00019082213176979668
84,0.00019082213176979668
321,0.00019082213176979668
314,0.00019082213176979668
-hydroxy-iso-pravastatin,0.00019082213176979668
h2antagonists,0.00019082213176979668
promote,0.00019082213176979668
didanosine-placebo,0.00019082213176979668
42,0.00019082213176979668
2.5-fold,0.00019082213176979668
maoi,0.00019082213176979668
catabolic,0.00019082213176979668
110,0.00019082213176979668
agent,0.0001907338476045961
75,0.00018845331452577163
fumarate,0.0001880767098580982
distribution,0.0001880767098580982
water,0.0001880767098580982
decarboxylase,0.0001880767098580982
levodopa/dopa,0.0001880767098580982
assay,0.0001880767098580982
antithrombotic,0.0001880519282988491
ssri-tcainteractions,0.0001880519282988491
typical,0.0001880519282988491
exist,0.0001880519282988491
definitively,0.0001880519282988491
order,0.0001880512800126466
antibiotics,0.00018803030515313068
negative,0.00018754968102263625
xanthine,0.0001866642394026119
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated",0.00018659132306630966
pyridine-treated,0.00018659132306630966
mesenteric,0.00018659132306630966
behavioral,0.0001864816261937241
route,0.00018635948146639159
clinicians,0.00018635948146639159
toxoids,0.00018635948146639159
0.4,0.00018553284499800426
systematically,0.0001850136660251911
69,0.00018456438686242915
slow,0.00018382682693840469
both,0.00018262465814700146
infusions,0.00018195281018962284
preliminary,0.00018169343058638265
spray,0.00018169343058638265
nicardipine,0.00018165871420838808
marketing,0.00018069505578910405
myopathy/rhabdomyolysis,0.0001793656169788438
fosinopril,0.0001793656169788438
tyrosine,0.0001793656169788438
warnings,0.0001793656169788438
infarction,0.00017872628923554235
female,0.00017817376168638432
objective,0.00017817376168638432
regard,0.00017817376168638432
treatments,0.00017817376168638432
51,0.0001779080414137102
bowel,0.0001779080414137102
fortified,0.0001779080414137102
antiepilepsy,0.0001778798084687283
r,0.0001778798084687283
32,0.00017772767457546745
unbound,0.00017772767457546745
58,0.00017772767457546745
cyp2c8,0.00017772767457546745
impact,0.00017772767457546745
enzyme-inducing,0.00017715993081202086
stomach,0.00017483173357735193
i,0.00017422799967226066
isolated,0.00017389170917758712
alterations,0.00017380580090797793
predominantly,0.00017380580090797793
absence,0.00017360320255643824
intrathecal,0.0001735843293921846
damage,0.0001735843293921846
deaths,0.0001735843293921846
our,0.0001735843293921846
46,0.00017355364334248335
boric,0.00017354811222780597
consequence,0.00017354811222780597
among,0.00017339356334999945
highly,0.00017314644197419238
intubating,0.00017268140558379663
nodal,0.00017268140558379663
opposite,0.00017268140558379663
within14,0.00017268140558379663
hyperuricemia,0.00017268140558379663
reliable,0.00017268140558379663
dose-dependently,0.00017268140558379663
6-10,0.00017268140558379663
modulates,0.00017268140558379663
two-second,0.00017268140558379663
enkephalinergic,0.00017268140558379663
way,0.00017268140558379663
contrary,0.00017268140558379663
node,0.00017268140558379663
a-v,0.00017268140558379663
typhoid,0.00017268140558379663
5-7.5,0.00017268140558379663
2.5-6,0.00017268140558379663
passages,0.00017268140558379663
3.1,0.00017268140558379663
3.9,0.00017268140558379663
dehydration,0.00017268140558379663
pacemaker,0.00017268140558379663
0.1-mg/kg,0.00017268140558379663
6/5,0.00017268140558379663
contortrostatin-induced,0.00017268140558379663
raising,0.00017268140558379663
systolic/diastolic,0.00017268140558379663
unrecognized,0.00017268140558379663
supine,0.00017268140558379663
mononitrate,0.00017268140558379663
1.75,0.00017268140558379663
air,0.00017268140558379663
allows,0.00017268140558379663
aggravated,0.00017268140558379663
succinylcholine,0.00017268140558379663
blunt,0.00017268140558379663
botulinum,0.00017268140558379663
resolution,0.00017268140558379663
1.30-2.35,0.00017268140558379663
hyperlocomotion,0.00017268140558379663
alkalizing,0.00017268140558379663
counteracted,0.00017268140558379663
lymphatic,0.00017268140558379663
b-blocking,0.00017268140558379663
prostin,0.00017268140558379663
antihypertensives,0.00017268140558379663
wedge,0.00017268140558379663
nitrates,0.00017268140558379663
hydroxymethylglutaryl,0.00017268140558379663
mda-mb-435,0.00017268140558379663
environmental,0.00017268140558379663
biological,0.00017268140558379663
conditioned,0.00017268140558379663
hepatoxicity,0.00017268140558379663
cas,0.00017268140558379663
abrupt,0.00017268140558379663
exerts,0.00017268140558379663
intrinsic,0.00017268140558379663
nonbenzodiazepine,0.00017268140558379663
ureidopenicillins,0.00017268140558379663
triazolopyridazines,0.00017268140558379663
non-depolarizing,0.00017268140558379663
reexacerbation,0.00017268140558379663
dose-response,0.00017268140558379663
tranquilizers,0.00017268140558379663
12-120,0.00017268140558379663
adjoining,0.00017268140558379663
powders,0.00017268140558379663
colonies,0.00017268140558379663
dasatinib-enhanced,0.00017268140558379663
stimulating,0.00017268140558379663
anti-resorptive,0.00017268140558379663
calcitonin,0.00017268140558379663
paget,0.00017268140558379663
rauwolfia,0.00017268140558379663
epidural,0.00017268140558379663
tinnitus,0.00017268140558379663
dangerous,0.00017268140558379663
combine,0.00017268140558379663
salmon,0.00017268140558379663
worsen,0.00017268140558379663
amyl,0.00017268140558379663
primates,0.00017268140558379663
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced",0.00017268140558379663
coeruleus,0.00017268140558379663
a5,0.00017268140558379663
a7,0.00017268140558379663
drying,0.00017268140558379663
ed95,0.00017268140558379663
exaggerated,0.00017268140558379663
proprietary,0.00017268140558379663
crescentic,0.00017268140558379663
stevens-johnson,0.00017268140558379663
glomerulonephritis,0.00017268140558379663
nitrite,0.00017268140558379663
inoculated,0.00017268140558379663
intrathecally,0.00017268140558379663
calculus,0.00017268140558379663
sodium/kg,0.00017268140558379663
ganglionic-blocking,0.00017268140558379663
ache,0.00017268140558379663
antiseptic,0.00017268140558379663
acetylcholinesterase,0.00017268140558379663
europe,0.00017268140558379663
forced,0.00017268140558379663
coumaphos/kg/day,0.00017268140558379663
sirnas,0.00017268140558379663
erythrocyte,0.00017268140558379663
bacillus,0.00017268140558379663
regulating,0.00017268140558379663
dasatinib-mediated,0.00017268140558379663
anticholinergic-like,0.00017268140558379663
oxytoca,0.00017268140558379663
somnolence,0.00017268140558379663
autoimmune,0.00017268140558379663
oculo-bulbar,0.00017268140558379663
klebsiella,0.00017268140558379663
evidently,0.00017268140558379663
subtilis,0.00017268140558379663
t24,0.00017268140558379663
hemodynamic,0.00017268140558379663
invasion,0.00017268140558379663
morphological,0.00017268140558379663
nuclear,0.00017268140558379663
markers,0.00017268140558379663
chromatin,0.00017268140558379663
condensation,0.00017268140558379663
mtor,0.00017268140558379663
automaticity,0.00017268140558379663
conductivity,0.00017268140558379663
synergy,0.00017268140558379663
triglycerides,0.00017268140558379663
sgot,0.00017268140558379663
represents,0.00017268140558379663
mdp,0.00017268140558379663
anti-cancer,0.00017268140558379663
hypokinesia,0.00017268140558379663
myocarditis,0.00017268140558379663
copd,0.00017268140558379663
appreciated,0.00017268140558379663
accumbal,0.00017268140558379663
strongyloidiasis,0.00017268140558379663
true,0.00017268140558379663
erythema,0.00017268140558379663
histamine-like,0.00017268140558379663
stupor,0.00017268140558379663
muscular,0.00017268140558379663
vecuronium-induced,0.00017268140558379663
antituberculous,0.00017268140558379663
anaphylactoid,0.00017268140558379663
disorientation,0.00017268140558379663
misuse,0.00017268140558379663
ptx-induced,0.00017268140558379663
99mtc-methylene,0.00017268140558379663
-gentamicin,0.00017268140558379663
diphosphonate,0.00017268140558379663
iga,0.00017268140558379663
term,0.00017268140558379663
dilation,0.00017268140558379663
bad,0.00017268140558379663
tubal,0.00017268140558379663
occasions,0.00017268140558379663
interesting,0.00017268140558379663
disc,0.00017268140558379663
adding,0.00017268140558379663
thiazide-type,0.00017268140558379663
protects,0.00017268140558379663
pemphigoid,0.00017268140558379663
thyroiditis,0.00017268140558379663
anticholinergic-type,0.00017268140558379663
incremental,0.00017268140558379663
100-500,0.00017268140558379663
neutralizing,0.00017268140558379663
anitagonism,0.00017268140558379663
bullous,0.00017268140558379663
"trans-3,4-dimethyl-4-",0.00017268140558379663
3-hydroxyphenyl,0.00017268140558379663
piperidine,0.00017268140558379663
.004,0.00017268140558379663
.005,0.00017268140558379663
graft-versus-host,0.00017268140558379663
enlargement,0.00017268140558379663
described,0.00017268140558379663
diminished,0.00017247926351848797
proposed,0.00017176938441298972
matrix,0.00017176938441298972
towards,0.00017176938441298972
confidence,0.00017104821864899478
fluoroquinolone,0.00017075970444602184
apart,0.00017047042882578634
n=12,0.00016945805126500346
single-dose,0.00016945805126500346
binds,0.00016945805126500346
supplemented,0.00016945805126500346
buffered,0.00016902166203947022
indicates,0.00016902166203947022
inactivated,0.00016902166203947022
fr,0.00016902166203947022
relaxant,0.00016902166203947022
leukemia,0.0001685653700880252
chemotherapeutic,0.0001682712775354922
cancers,0.0001682712775354922
injections,0.0001682712775354922
analyzed,0.0001682712775354922
1a2,0.0001682490236107892
proportion,0.0001682490236107892
already,0.00016818478467384157
upon,0.0001670374009249409
enzyme-,0.00016564654111461685
feso4,0.00016564654111461685
p-glycoprotein,0.00016564654111461685
125mg,0.00016564654111461685
synthetic,0.00016564654111461685
100-mg,0.00016564654111461685
extensive,0.00016564654111461685
+/-,0.00016550114994884346
fi,0.00016550114994884346
mao-a,0.0001654395137248299
ldl-c,0.00016534550106073187
infection,0.00016534550106073187
gram-negative,0.00016534550106073187
chick,0.00016534550106073187
rashes,0.00016534550106073187
stress,0.00016534550106073187
cecectomized,0.00016534550106073187
crossover,0.000165201164557649
iv,0.00016513905381720928
alert,0.0001647022498659778
remeron,0.00016325924761706467
soltab,0.00016325924761706467
beginning,0.00016325924761706467
interference,0.0001631654747633604
coumarin-derivative,0.00016292796562544787
meq/l,0.00016288221632876354
uptake,0.00016261373308656957
statistically,0.00016253315589942474
placebo,0.00016218101335274682
interferon,0.00016214829338734305
prolongs,0.00016144912195004135
3.6-fold,0.0001613959202736437
postdose,0.0001613959202736437
eight,0.0001613959202736437
recent,0.0001613959202736437
1.5-fold,0.0001613959202736437
electrocardiographic,0.0001610510292935352
responding,0.00016092600253303502
additional,0.00016050145554136197
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-",0.0001599511103080875
antimicrobial,0.0001597958761161422
hyperbilirubinemia,0.00015942452892225845
proleukin-induced,0.00015942452892225845
tc,0.0001589972420588115
300-mg,0.0001589972420588115
methods,0.00015893663388510948
alkaloid,0.00015893564901836577
hour,0.00015886020263589096
derivatives,0.00015840632041430602
disoproxil,0.00015836925736256724
tenofovir,0.00015836925736256724
fractional,0.00015836925736256724
fibrosis,0.00015836925736256724
strain,0.00015836925736256724
investigate,0.00015836925736256724
carbidopa-levodopa,0.00015836925736256724
whom,0.0001581120002696057
motor,0.0001577361547758782
one-third,0.00015654585568836143
typically,0.00015653806046889152
arrythmias,0.00015653806046889152
122,0.00015653806046889152
impairing,0.00015653806046889152
half,0.00015653806046889152
pointe,0.00015653806046889152
antibacterials,0.00015653806046889152
metabolised,0.00015653806046889152
uricosuric,0.00015653806046889152
tubule,0.00015653806046889152
tmax,0.00015653806046889152
doubling,0.00015653806046889152
49,0.00015653806046889152
intestine,0.00015653806046889152
bronchodilators,0.00015639488015339875
beta-1a,0.00015623316780610796
-receptor,0.00015623316780610796
conjugation,0.0001559739945711236
blocker,0.0001559739945711236
phenobarbital,0.00015594730513079913
d,0.0001558634282691207
antibiotic,0.00015541428924481515
maximal,0.0001553691580071792
3-day,0.00015528861487124068
present,0.00015525101871960434
de,0.00015390312519225624
beyond,0.00015366211450007494
procaine,0.0001529250955624173
maalox,0.00015206333442918663
ng/ml,0.00015206333442918663
life,0.00015206333442918663
disintegrating,0.00015206333442918663
enzymatic,0.00015206333442918663
hearing,0.00015161560888976577
antiretroviral,0.00015122552246293886
week,0.00015094776779900343
perindopril/perindoprilat,0.00015078173222216051
6-thiouric,0.00015078173222216051
mercaptopurine/azathioprine,0.00015078173222216051
hiv-infected,0.00015078173222216051
canine,0.00015078173222216051
formation,0.00015069374243137368
six,0.00015024588537049244
torsades,0.00015024588537049244
q.d,0.00015024588537049244
comparable,0.00015007269698741332
diltiazem,0.0001498290697266036
undergo,0.00014890627200037088
circulation,0.00014890627200037088
so,0.00014890627200037088
multi,0.0001484677011236446
compound,0.0001484677011236446
high-frequency,0.0001484677011236446
minerals,0.0001484677011236446
ventilation,0.0001484677011236446
checkerboard,0.0001484677011236446
kinds,0.0001484677011236446
worse,0.0001484677011236446
calcium-channel-blocking,0.0001484677011236446
condition,0.0001484677011236446
5-htv,0.0001484677011236446
fici,0.0001484677011236446
iva-sensitive,0.0001484677011236446
gvia/omega-agatoxin,0.0001484677011236446
q-type,0.0001484677011236446
refractory,0.0001484677011236446
fibric,0.0001484677011236446
premedicated,0.0001484677011236446
background,0.0001484677011236446
hydroxide-containing,0.0001484677011236446
hydroxide-,0.0001484677011236446
glatiramer,0.0001484677011236446
inconclusive,0.0001484677011236446
sclerosis,0.0001484677011236446
opiate,0.0001484677011236446
insulin-dependent,0.0001484677011236446
pill,0.0001484677011236446
non-opioid,0.0001484677011236446
several-,0.0001484677011236446
hypo-prothrombinemic,0.0001484677011236446
murine,0.0001484677011236446
models,0.0001484677011236446
lymphoma,0.0001484677011236446
nimodipine/omega-conotoxin,0.0001484677011236446
diphen-hydramine,0.0001484677011236446
cystic,0.0001484677011236446
via-resistant,0.0001484677011236446
gvia-sensitive,0.0001484677011236446
myopathy,0.0001484677011236446
presumptive,0.0001484677011236446
anti-arrhythmic,0.0001484677011236446
coupled,0.0001484677011236446
3000,0.0001484677011236446
organophosphorous,0.0001484677011236446
cavity,0.0001484677011236446
rifamipicin,0.0001484677011236446
coincide,0.0001484677011236446
lomefloxacin,0.0001484677011236446
behave,0.0001484677011236446
0,0.00014843363428784784
synthesis,0.0001476567297894471
via,0.00014753837797987224
proceed,0.00014693897465600791
curariform,0.00014693897465600791
addicts,0.00014693897465600791
artery,0.00014693897465600791
broad-spectrum,0.00014693897465600791
describing,0.00014693897465600791
losses,0.00014693897465600791
culture,0.00014693897465600791
retinal,0.00014693897465600791
transduction,0.00014693897465600791
alertness,0.00014693897465600791
fibrate,0.00014693897465600791
rises,0.00014693897465600791
vital,0.00014693897465600791
enteric,0.00014693897465600791
stereoisomer,0.00014693897465600791
fade,0.00014693897465600791
separated,0.00014693897465600791
inefficacy,0.00014693897465600791
theophylline-related,0.00014693897465600791
nonfailing,0.00014693897465600791
electrolytes,0.00014693897465600791
concealed,0.00014693897465600791
neoplastic,0.00014693897465600791
hdac,0.00014693897465600791
disease,0.00014684021588418084
could,0.00014674080718246607
eye,0.0001465126908480885
precipitate,0.0001458894116319609
role,0.0001458894116319609
changed,0.00014375531578481038
immediately,0.00014205625431018554
filtrated,0.00014197406199745188
99.5,0.00014197406199745188
99.3,0.00014197406199745188
to10,0.00014197406199745188
hazard,0.00014197406199745188
discontinuance,0.00014197406199745188
rheumatoid,0.00014197406199745188
reach,0.00014197406199745188
schizophrenia,0.00014197406199745188
enough,0.00014185101422659052
delivery,0.00014185101422659052
watched,0.00014185101422659052
throughout,0.00014185101422659052
occurs,0.00014185101422659052
precipitated,0.00014185101422659052
syncope,0.00014185101422659052
catecholamine,0.00014185101422659052
revealed,0.00014123297142520919
intensity,0.00014123297142520919
development,0.00014087045232769047
having,0.00014087045232769047
cognitive,0.00014020379741108702
returned,0.00014016113139669883
production,0.00013965159201023702
product,0.00013965159201023702
enterohepatic,0.00013902882283589602
functional,0.0001387180283287659
pigeons,0.00013861604962350782
intraperitoneally,0.00013861604962350782
comparison,0.00013861604962350782
versus,0.00013856660877475946
corrected,0.00013856660877475946
improves,0.00013856660877475946
examined,0.00013856660877475946
examine,0.00013856660877475946
same,0.00013814778243115278
7,0.00013759781396815995
ml/min,0.0001359646026968253
examining,0.00013519088550539848
group,0.00013519088550539848
symptoms,0.0001349829179634332
point,0.00013479507568425753
pre-mexitil,0.00013479507568425753
determine,0.00013461335235032124
supplement,0.00013452580606121423
-erythro-fluorocitrate,0.00013404149123297238
drinking,0.00013384451746156767
compromised,0.00013384451746156767
conclude,0.00013384451746156767
bp,0.00013384451746156767
output,0.00013384451746156767
enterocolitis,0.00013384451746156767
hoof,0.00013384451746156767
xr,0.00013384451746156767
augmentin,0.00013384451746156767
intermediate,0.00013384451746156767
rapid,0.00013384451746156767
fluid,0.00013384451746156767
characterized,0.00013384451746156767
dysesthesia,0.00013384451746156767
cardioactive,0.0001336505715978653
various,0.00013334939066222962
counts,0.00013324079006105105
adjustments,0.00013323108477258927
cancer,0.00013249956885319492
individuals,0.00013150712161269507
instances,0.00013144569545719964
inducing,0.00013138945528079482
fluvoxamine,0.00012985716608582276
unaffected,0.0001296902407896816
occurred,0.00012915981210248617
spinal,0.0001286659802730572
procedure,0.0001286659802730572
endorphinergic,0.0001286659802730572
placebo-treated,0.0001286659802730572
r=,0.0001286659802730572
indication,0.0001286659802730572
transport,0.00012857240203389964
arthritis,0.00012837391142439536
cycling,0.00012810616444336453
diffusion,0.00012786986050994376
escalating,0.0001269737686624417
min,0.00012654088031394117
vasoconstriction,0.00012564788477176236
apoptosis,0.00012557489415132572
depressed,0.00012491973776040943
cholesterol,0.0001245801875101593
cytotoxic,0.0001243658664968894
fewer,0.0001243658664968894
member,0.00012382062978399944
took,0.00012329013879686102
unusually,0.00012329013879686102
free,0.00012314278939318246
alteration,0.00012246787704250917
target,0.00012213732493382423
poor,0.0001221368860053751
dolasetron,0.0001221368860053751
primarily,0.0001221368860053751
temporarily,0.00012184841953610803
working,0.00012176338400082809
properly,0.00012176338400082809
into,0.00012176338400082809
qt,0.00012131785780211679
breakdown,0.0001203422303298618
arterial,0.00012014408204907845
mg/m2,0.00012004155865941168
"tramadol.4,5",0.00012004155865941168
388,0.00012004155865941168
"drugs.1,3",0.00012004155865941168
health,0.00011978323941108648
iron,0.00011913203847369047
nucleoside,0.00011913203847369047
considering,0.00011913203847369047
1/3,0.00011913203847369047
usage,0.00011913203847369047
1/4,0.00011913203847369047
caffeine-containing,0.00011913203847369047
5-ht1b/1d,0.00011913203847369047
releaser,0.00011913203847369047
dictate,0.00011913203847369047
seem,0.00011913203847369047
one-tenth,0.00011913203847369047
1/10,0.00011913203847369047
notably,0.00011913203847369047
ofthe,0.00011913203847369047
short,0.00011913203847369047
third,0.00011913203847369047
methotrexate-related,0.00011913203847369047
needs,0.00011913203847369047
continued,0.00011913203847369047
replace,0.00011913203847369047
orthostatic,0.00011897746326017256
chromatography,0.00011876581557412891
1.3,0.00011876581557412891
assays,0.00011876581557412891
glucuronidation,0.00011876581557412891
cortical,0.00011876581557412891
meals,0.00011876581557412891
structurally,0.00011876581557412891
periods,0.00011876581557412891
immune,0.00011876581557412891
epoxide,0.00011876581557412891
further,0.00011844321320952922
combinations,0.00011826513627344326
duodenal,0.0001181052658467685
mg/l,0.0001181052658467685
median,0.0001181052658467685
catabolism,0.0001181052658467685
competition,0.0001181052658467685
schizoaffective,0.0001181052658467685
converted,0.0001181052658467685
magnitude,0.0001181052658467685
hydroxylation,0.0001181052658467685
disorder,0.0001181052658467685
slowly,0.0001181052658467685
contraceptive,0.00011803521457753874
positive,0.00011797483523434682
attenuating,0.0001175127631597439
parkinsons,0.0001175127631597439
prolonging,0.0001175127631597439
failed,0.0001175127631597439
vs,0.00011744174825945031
done,0.00011736936283790467
0.05,0.0001167478247985354
international,0.0001167478247985354
chewable/dispersible,0.0001167478247985354
inhibitory,0.00011599152854568917
gi,0.00011573206564330363
improved,0.00011511408494491171
adenocarcinomas,0.00011511408494491171
attenuate,0.00011511408494491171
withdrawal,0.0001150874810363911
4-6,0.00011501170724914633
extend,0.00011501170724914633
h1,0.00011265490335499173
children,0.00011265490335499173
skin,0.00011265490335499173
ampicillin/amoxicillin,0.00011265490335499173
rash,0.00011265490335499173
novel,0.00011265490335499173
displayed,0.00011265490335499173
adrenal,0.00011265490335499173
<,0.00011265490335499173
0.09-0.13,0.00011265490335499173
upper,0.00011265490335499173
amlodipine/valsartan,0.00011265490335499173
nose,0.00011265490335499173
mydriasis,0.00011265490335499173
antiviral,0.00011265490335499173
atropinization,0.00011265490335499173
dryness,0.00011265490335499173
antibacterial,0.00011265490335499173
insp,0.00011265490335499173
earlier,0.00011265490335499173
mental,0.0001123500106923192
anti-depressants,0.0001123500106923192
measured,0.00011097680149751987
skills,0.00011001996807835646
glucuronide,0.00010990482321804329
tuberculosis,0.00010990482321804329
limit,0.00010990482321804329
250,0.00010990482321804329
n=18,0.00010990482321804329
intramuscular,0.00010990482321804329
dysrhythmias,0.00010949504168134006
p.o,0.00010949504168134006
2d3,0.00010936561417529411
oh,0.00010936561417529411
"1,25",0.00010936561417529411
vasoconstrictor,0.00010936561417529411
humans,0.00010923173248467144
er,0.00010886611463511997
subtypes,0.00010886611463511997
0.15,0.00010886611463511997
dna,0.00010886611463511997
double-blind,0.00010886611463511997
intravitreal,0.00010886611463511997
regular,0.00010886611463511997
depressive,0.00010886611463511997
diagnostic,0.00010886611463511997
future,0.00010886611463511997
>,0.00010886611463511997
useful,0.00010886611463511997
unexpected,0.00010886611463511997
green,0.00010886611463511997
differential,0.00010886611463511997
hyaluronan,0.00010886611463511997
voltage-dependent,0.00010886611463511997
descending,0.00010886611463511997
cycle,0.00010844929899134215
package,0.00010844929899134215
dosed,0.00010818017731528684
anxiogenic,0.00010818017731528684
cgs,0.00010818017731528684
vasodilating,0.00010818017731528684
21680,0.00010818017731528684
account,0.00010818017731528684
lyase,0.00010818017731528684
fixed,0.00010818017731528684
conditions,0.00010766832073749733
cohort,0.00010734236534903907
hey,0.00010734236534903907
chondroitin,0.00010689857510837175
heparinase,0.00010689857510837175
abc,0.00010689857510837175
metastasis,0.00010663989869574841
msec,0.00010636272825670368
stimulant,0.00010636272825670368
dsst,0.00010636272825670368
pyridine,0.00010636272825670368
1.0,0.00010625832144006697
appeared,0.00010625786476603505
adolescent,0.00010617366110554638
cross-reactivity,0.00010617366110554638
screen,0.00010617366110554638
consciousness,0.00010617366110554638
asparagine,0.00010617366110554638
practice,0.00010617366110554638
tetracycline,0.00010617366110554638
side-effects,0.00010594591261281483
poisoning,0.00010594591261281483
overdose,0.00010594591261281483
insulin,0.00010568345841066584
maintenance,0.00010552919186057608
non-linear,0.00010479613076352923
extremely,0.00010479613076352923
halved,0.00010479613076352923
forevidence,0.00010479613076352923
100-300,0.00010479613076352923
article,0.00010416449662831173
94.8,0.00010416449662831173
16-fold,0.00010416449662831173
7-fold,0.00010416449662831173
60-mg,0.00010416449662831173
96.3,0.00010416449662831173
repeated,0.00010416449662831173
microsomes,0.00010416449662831173
controlled-release,0.00010416449662831173
600-mg,0.00010416449662831173
dosages,0.00010402209719662103
regularly,0.00010199260952226119
kept,0.00010199260952226119
method,0.00010199260952226119
involvement,0.00010199260952226119
pharmacology,0.0001015137266193733
fashion,0.0001008344391303373
percentage,0.0001008344391303373
forms,0.0001008344391303373
lesser,0.0001008344391303373
types,0.00010020438266722387
wistar,0.00010020438266722387
over,0.00010017985968324705
insert,9.975568064735096e-05
79,9.933694881858468e-05
interrupt,9.933694881858468e-05
co-administer,9.933694881858468e-05
achieved,9.933694881858468e-05
inadvisable,9.933694881858468e-05
mind,9.933694881858468e-05
chemical,9.933694881858468e-05
resemblance,9.933694881858468e-05
persons,9.89668774122876e-05
levodopa/dopa-decarboxylase,9.89668774122876e-05
besides,9.89668774122876e-05
l-type,9.89668774122876e-05
hypnotic,9.89668774122876e-05
non-cyp3a4,9.89668774122876e-05
iva,9.89668774122876e-05
luteinizing,9.89668774122876e-05
n=29,9.89668774122876e-05
mao-b,9.89668774122876e-05
naloxone-sensitive,9.89668774122876e-05
elicit,9.89668774122876e-05
vanillylmandelic,9.89668774122876e-05
bolus-ifl,9.89668774122876e-05
gvia,9.89668774122876e-05
n=24,9.89668774122876e-05
belladonna,9.89668774122876e-05
query,9.89668774122876e-05
invalidate,9.89668774122876e-05
hela,9.89668774122876e-05
u251,9.89668774122876e-05
hepg2,9.89668774122876e-05
planned,9.89668774122876e-05
guardians,9.89668774122876e-05
submaximal,9.89668774122876e-05
documented,9.89668774122876e-05
recommended.levetiracetam,9.89668774122876e-05
progesterone,9.89668774122876e-05
extremities,9.89668774122876e-05
half-,9.89668774122876e-05
convert,9.89668774122876e-05
pheochromocytoma,9.89668774122876e-05
0.2-0.5,9.89668774122876e-05
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle",9.89668774122876e-05
delivered,9.89668774122876e-05
chicken,9.89668774122876e-05
experimental,9.89668774122876e-05
prednisone/prednisolone,9.89668774122876e-05
prostatitis,9.89668774122876e-05
uncomplicated,9.89668774122876e-05
gfp,9.89668774122876e-05
complicated,9.89668774122876e-05
ethinylestradiol/levonorgestrol,9.89668774122876e-05
repeat,9.89668774122876e-05
-warfarin,9.89668774122876e-05
promoter,9.89668774122876e-05
encoding,9.89668774122876e-05
cdna,9.89668774122876e-05
-actin,9.89668774122876e-05
minimize,9.89668774122876e-05
bosentan-,9.89668774122876e-05
mmol/day,9.89668774122876e-05
lipid-lowering,9.89668774122876e-05
fluorescent,9.89668774122876e-05
induces,9.89668774122876e-05
8-23,9.89668774122876e-05
pregnancy,9.89668774122876e-05
16-34,9.89668774122876e-05
technique,9.89668774122876e-05
maybe,9.89668774122876e-05
hydrophilic,9.89668774122876e-05
saline,9.89668774122876e-05
gel,9.89668774122876e-05
heparin-induced,9.89668774122876e-05
6-mp/aza,9.89668774122876e-05
peroral,9.89668774122876e-05
ssris,9.89668774122876e-05
connection,9.89668774122876e-05
ischemia,9.89668774122876e-05
hot-plate,9.89668774122876e-05
light/dark,9.89668774122876e-05
adenosine,9.89668774122876e-05
nd,9.89668774122876e-05
parallel,9.89668774122876e-05
refer,9.879507162258161e-05
conclusion,9.879507162258161e-05
provide,9.879507162258161e-05
supporting,9.879507162258161e-05
p450iid6,9.872212866268715e-05
125-mg,9.872212866268715e-05
t,9.872212866268715e-05
subsequently,9.839157655400221e-05
bepridil,9.813676594405685e-05
volume,9.807535245520693e-05
tolerated,9.632454239305588e-05
cocaine-induced,9.617276250883933e-05
drowsiness,9.617276250883933e-05
endotoxin-induced,9.617276250883933e-05
recognized,9.617276250883933e-05
protective,9.617276250883933e-05
experiencing,9.617276250883933e-05
noradrenergic,9.617276250883933e-05
injury,9.617276250883933e-05
congeners,9.617276250883933e-05
persistent,9.617276250883933e-05
confirmed,9.617276250883933e-05
paclitaxel-induced,9.617276250883933e-05
-mediated,9.617276250883933e-05
neuron,9.617276250883933e-05
drops,9.617276250883933e-05
hand,9.617276250883933e-05
e2,9.617276250883933e-05
breakthrough,9.617276250883933e-05
iatrogenic,9.617276250883933e-05
flow,9.617276250883933e-05
kinases,9.617276250883933e-05
month,9.617276250883933e-05
coumaphos/kg,9.617276250883933e-05
abl,9.617276250883933e-05
preclinical,9.617276250883933e-05
cure,9.617276250883933e-05
factors,9.617276250883933e-05
symptomatic,9.617276250883933e-05
src,9.617276250883933e-05
symptomatology,9.617276250883933e-05
immunization,9.617276250883933e-05
pathway,9.604800483009601e-05
literature,9.571755095982848e-05
pharmacological,9.560195767344126e-05
302,9.538629009386845e-05
5-,9.538629009386845e-05
ages,9.538629009386845e-05
clinician,9.538629009386845e-05
~28,9.538629009386845e-05
accelerate,9.538629009386845e-05
detoxification,9.538629009386845e-05
~36,9.538629009386845e-05
142,9.538629009386845e-05
68,9.538629009386845e-05
50-mg,9.538629009386845e-05
251,9.538629009386845e-05
s.d,9.538629009386845e-05
averaged,9.538629009386845e-05
university,9.538629009386845e-05
non-matched,9.538629009386845e-05
andcmin,9.538629009386845e-05
threatening,9.538629009386845e-05
elimination.14,9.538629009386845e-05
354,9.538629009386845e-05
conclusive,9.538629009386845e-05
102,9.538629009386845e-05
-19,9.538629009386845e-05
milk,9.538629009386845e-05
73,9.538629009386845e-05
1984,9.538629009386845e-05
wales,9.538629009386845e-05
alternate-day,9.538629009386845e-05
historicalcontrol,9.538629009386845e-05
"1,000",9.538629009386845e-05
life-,9.538629009386845e-05
rabbit,9.538629009386845e-05
useof,9.538629009386845e-05
metabolizing,9.538629009386845e-05
consequent,9.538629009386845e-05
60mg,9.538629009386845e-05
competing,9.538629009386845e-05
1-week,9.538629009386845e-05
orlistat-orlistat,9.538629009386845e-05
fell,9.538629009386845e-05
2.3,9.538629009386845e-05
gritty,9.538629009386845e-05
sulfide,9.538629009386845e-05
preservative,9.538629009386845e-05
substance,9.538629009386845e-05
emptying,9.538629009386845e-05
drs,9.538629009386845e-05
uric,9.538629009386845e-05
hypoxanthine,9.538629009386845e-05
methadone-maintenance,9.538629009386845e-05
rimmer,9.538629009386845e-05
piperacillin,9.538629009386845e-05
slices,9.538629009386845e-05
evidenced,9.538629009386845e-05
richens,9.538629009386845e-05
allopurinol,9.538629009386845e-05
265,9.538629009386845e-05
delaying,9.538629009386845e-05
3.8-fold,9.538629009386845e-05
oral-dose,9.538629009386845e-05
0-8,9.538629009386845e-05
denotes,9.538629009386845e-05
20-33,9.538629009386845e-05
nc,9.538629009386845e-05
pediatrics,9.538629009386845e-05
99.2,9.538629009386845e-05
0.022,9.538629009386845e-05
accompany,9.538629009386845e-05
190,9.538629009386845e-05
269,9.538629009386845e-05
matched,9.538629009386845e-05
0.013,9.538629009386845e-05
479,9.538629009386845e-05
nonfunctioning,9.538629009386845e-05
drop,9.538629009386845e-05
lactulose-induced,9.538629009386845e-05
97.5,9.538629009386845e-05
possibilities,9.538629009386845e-05
1-,9.538629009386845e-05
representing,9.538629009386845e-05
xl,9.538629009386845e-05
hydroxylated,9.538629009386845e-05
albumin,9.538629009386845e-05
totally,9.538629009386845e-05
oxybutynin,9.538629009386845e-05
marketed,9.538629009386845e-05
37,9.538629009386845e-05
biologic,9.538629009386845e-05
ditropan,9.538629009386845e-05
12-fold,9.538629009386845e-05
auc0-120hr,9.538629009386845e-05
20-mg,9.538629009386845e-05
minute,9.538629009386845e-05
10-fold,9.538629009386845e-05
reflects,9.538629009386845e-05
1.34-fold,9.538629009386845e-05
15-fold,9.538629009386845e-05
leave,9.538629009386845e-05
points,9.538629009386845e-05
psychomotor,9.518028637878206e-05
performance,9.518028637878206e-05
parkinsonian,9.397334029248583e-05
component,9.397334029248583e-05
growth,9.397334029248583e-05
mechanisms,9.397334029248583e-05
82,9.380686306947883e-05
bioavailabillty,9.362361445808265e-05
6.6,9.362361445808265e-05
200-mg,9.362361445808265e-05
cause-and-effect,9.307920391110613e-05
derived,9.307920391110613e-05
diabetics,9.307920391110613e-05
neutrophil,9.307920391110613e-05
congestive,9.273746070059818e-05
cns-active,9.273746070059818e-05
demonstrate,9.268391620143035e-05
vs.,9.10538668386085e-05
dogs,9.094236609663575e-05
pulmonary,9.064264894753649e-05
cefditoren,9.053280396287278e-05
excluded,9.028635097907411e-05
h,8.974306544407007e-05
variable,8.942587032034766e-05
false-positive,8.906810386211106e-05
qrs,8.906810386211106e-05
subcutaneous,8.906810386211106e-05
mode,8.906810386211106e-05
warrant,8.906810386211106e-05
nph,8.906810386211106e-05
0-24,8.906810386211106e-05
stereoisomers,8.906810386211106e-05
r-value,8.906810386211106e-05
estimates,8.906810386211106e-05
comprehensive,8.906810386211106e-05
s-,8.906810386211106e-05
o,8.906810386211106e-05
cmc-cys7.3,8.906810386211106e-05
lack,8.906810386211106e-05
dissolution,8.906810386211106e-05
smoking,8.906810386211106e-05
isolates,8.906810386211106e-05
equipotent,8.906810386211106e-05
maintain,8.892637078039556e-05
1-mg,8.892637078039556e-05
measurable,8.892637078039556e-05
usp,8.8893007699542e-05
qid,8.806576489595042e-05
kg,8.797231988011411e-05
negatively,8.797231988011411e-05
conversion,8.797231988011411e-05
delayed,8.766741735888317e-05
impeding,8.75299180440603e-05
megestrol,8.75299180440603e-05
probably,8.743302890446003e-05
detected,8.742551122764564e-05
bile,8.742551122764564e-05
intervals,8.732124289190235e-05
stadol,8.569459662965961e-05
ns,8.569459662965961e-05
auc0-24hr,8.470355061152013e-05
day5,8.470355061152013e-05
sensitive,8.470355061152013e-05
glutathione,8.470355061152013e-05
exchange,8.470355061152013e-05
anionic,8.470355061152013e-05
absorbed,8.470355061152013e-05
become,8.410127100377807e-05
displacing,8.410127100377807e-05
color,8.410127100377807e-05
1-2,8.410127100377807e-05
cyclosporine-treated,8.410127100377807e-05
indeed,8.410127100377807e-05
inter-patient,8.410127100377807e-05
double,8.410127100377807e-05
later,8.410127100377807e-05
oxypurines,8.410127100377807e-05
scintigraphy,8.410127100377807e-05
meal,8.410127100377807e-05
0.025,8.410127100377807e-05
treatment-resistant,8.410127100377807e-05
considerable,8.410127100377807e-05
colonic,8.410127100377807e-05
clearances,8.410127100377807e-05
followed,8.39937277902214e-05
hypotension.cimetidine,8.242791272572436e-05
bumetanide-induced,8.242791272572436e-05
blunts,8.242791272572436e-05
preparation,8.242791272572436e-05
depletion,8.242791272572436e-05
natriuresis,8.242791272572436e-05
mesylate,8.239643271223951e-05
myelosuppression,8.223199329038255e-05
110-200,8.223199329038255e-05
problem,8.223199329038255e-05
alternate,8.223199329038255e-05
epinephrine,8.223199329038255e-05
mixing,8.223199329038255e-05
ca,8.223199329038255e-05
phenelzine,8.223199329038255e-05
tranylcypromine,8.223199329038255e-05
hc1,8.223199329038255e-05
sequence,8.223199329038255e-05
safe,8.223199329038255e-05
direct,8.220016423299281e-05
150,8.136584945095393e-05
ng,8.105038238381823e-05
10th,8.105038238381823e-05
15.1,8.105038238381823e-05
threefold,8.105038238381823e-05
completion,8.105038238381823e-05
170,8.105038238381823e-05
"4,8",8.105038238381823e-05
stered,8.105038238381823e-05
3.3-fold,8.105038238381823e-05
10-day,8.105038238381823e-05
admini,8.105038238381823e-05
2.3-fold,8.105038238381823e-05
230,8.105038238381823e-05
magnesium-aluminum,8.105038238381823e-05
12-hour,8.105038238381823e-05
auc0-12,8.105038238381823e-05
c12hr,8.105038238381823e-05
q24h,8.105038238381823e-05
g/h/ml,8.105038238381823e-05
17.8,8.105038238381823e-05
12.08,8.105038238381823e-05
ee,8.105038238381823e-05
lng,8.105038238381823e-05
hr/ml,8.105038238381823e-05
multidose,8.105038238381823e-05
4.55,8.105038238381823e-05
5.4,8.105038238381823e-05
samples,7.916979394118062e-05
hplc,7.916979394118062e-05
liquid,7.916979394118062e-05
improve,7.916979394118062e-05
overload,7.916979394118062e-05
psychopathology,7.916979394118062e-05
0.6,7.916979394118062e-05
red,7.916979394118062e-05
antifungal,7.898973354381056e-05
1500,7.824686114243917e-05
years,7.824686114243917e-05
estrogen,7.824686114243917e-05
aldehyde,7.824686114243917e-05
published,7.824686114243917e-05
cyp2a6,7.824686114243917e-05
seven,7.80940662410412e-05
catalyzed,7.80940662410412e-05
kidney,7.80940662410412e-05
traditional,7.678962532464695e-05
strains,7.678962532464695e-05
molecular,7.678962532464695e-05
randomized,7.678962532464695e-05
means,7.678962532464695e-05
activation,7.678962532464695e-05
lines,7.678962532464695e-05
conflicting,7.674744960917135e-05
sufficient,7.674744960917135e-05
toxicology,7.674744960917135e-05
properties,7.670473508891718e-05
minimal,7.668857743414748e-05
first-pass,7.600993226763997e-05
recipients,7.600993226763997e-05
81,7.600993226763997e-05
subject,7.559120043876266e-05
primate,7.559120043876266e-05
mainly,7.559120043876266e-05
-hydroxy,7.559120043876266e-05
conversely,7.559120043876266e-05
middle-aged,7.559120043876266e-05
8.1,7.559120043876266e-05
7.2,7.559120043876266e-05
area-under-the-curve,7.559120043876266e-05
oil-concomitant,7.559120043876266e-05
11-fold,7.559120043876266e-05
0-,7.559120043876266e-05
375-mg,7.559120043876266e-05
day9,7.559120043876266e-05
49-fold,7.559120043876266e-05
14-day,7.559120043876266e-05
13-fold,7.559120043876266e-05
nonsteroial,7.559120043876266e-05
74,7.559120043876266e-05
94,7.559120043876266e-05
88,7.559120043876266e-05
leads,7.559120043876266e-05
theophylline-containing,7.559120043876266e-05
endotoxin-treated,7.559120043876266e-05
lowers,7.559120043876266e-05
colestipol-concomitant,7.559120043876266e-05
cholestyramine-concomitant,7.559120043876266e-05
ten-subject,7.559120043876266e-05
impairs,7.559120043876266e-05
b2,7.559120043876266e-05
transport-related,7.559120043876266e-05
remained,7.559120043876266e-05
psychiatric,7.559120043876266e-05
physiologic,7.559120043876266e-05
111,7.559120043876266e-05
lessened,7.559120043876266e-05
members,7.559120043876266e-05
urate,7.559120043876266e-05
therophylline,7.559120043876266e-05
concomitan,7.559120043876266e-05
5.4-fold,7.559120043876266e-05
clcr=15,7.559120043876266e-05
114,7.559120043876266e-05
2.2,7.559120043876266e-05
98,7.559120043876266e-05
sequestrants,7.559120043876266e-05
twice-daily,7.559120043876266e-05
steady-,7.559120043876266e-05
3.5-fold,7.559120043876266e-05
n=16,7.559120043876266e-05
sublingual,7.504932324275959e-05
ml/h,7.504932324275959e-05
tacrolimus-treated,7.504932324275959e-05
biliary,7.504932324275959e-05
antiepileptic,7.463880687774704e-05
property,7.410498769333529e-05
11.5,7.345378675593928e-05
87,7.345378675593928e-05
lithium,7.345378675593928e-05
stimulatory,7.345378675593928e-05
non-comparative,7.345378675593928e-05
pharmacological/pharmacodynamic,7.345378675593928e-05
warfarin-vitamin,7.345378675593928e-05
coeruleus/a5/a7,7.345378675593928e-05
post-mortem,7.345378675593928e-05
imaging,7.345378675593928e-05
measurements,7.345378675593928e-05
behavioural,7.345378675593928e-05
13.7,7.345378675593928e-05
reversing,7.345378675593928e-05
13.8,7.345378675593928e-05
7.7,7.345378675593928e-05
2.7,7.345378675593928e-05
knockdown,7.345378675593928e-05
opioid-induced,7.345378675593928e-05
369,7.345378675593928e-05
0.8,7.345378675593928e-05
appropriateness,7.345378675593928e-05
9.2+/-1.8,7.345378675593928e-05
allowing,7.345378675593928e-05
2.5+/-0.6,7.345378675593928e-05
residual,7.345378675593928e-05
diminishing,7.345378675593928e-05
inhospital,7.345378675593928e-05
quicker,7.345378675593928e-05
3.0+/-0.9,7.345378675593928e-05
self,7.345378675593928e-05
peripherally,7.345378675593928e-05
1400,7.345378675593928e-05
anti-,7.345378675593928e-05
367,7.345378675593928e-05
rate-decreasing,7.345378675593928e-05
5.8+/-2.3,7.345378675593928e-05
protect,7.345378675593928e-05
scores,7.345378675593928e-05
lotensin,7.345378675593928e-05
predisposing,7.345378675593928e-05
perioperative,7.345378675593928e-05
intracranial,7.345378675593928e-05
aggravating,7.345378675593928e-05
provoke,7.345378675593928e-05
theophylline-quinolone,7.345378675593928e-05
contractile,7.345378675593928e-05
kinetics,7.345378675593928e-05
coenzyme,7.345378675593928e-05
abased,7.345378675593928e-05
organisms,7.345378675593928e-05
bactercidal,7.345378675593928e-05
heartbeat,7.345378675593928e-05
hyperreninemia,7.345378675593928e-05
necessitating,7.345378675593928e-05
intravascular,7.345378675593928e-05
e.w,7.345378675593928e-05
501,7.345378675593928e-05
11-28,7.345378675593928e-05
-blocking,7.345378675593928e-05
hydroxylase,7.345378675593928e-05
emission,7.345378675593928e-05
bombesin-enhanced,7.345378675593928e-05
stereological,7.345378675593928e-05
striatal,7.345378675593928e-05
administer,7.345378675593928e-05
sirna,7.345378675593928e-05
positron,7.345378675593928e-05
immunoreactivity,7.345378675593928e-05
tomography,7.345378675593928e-05
almost,7.345378675593928e-05
hydroxylase-positive,7.345378675593928e-05
successive,7.345378675593928e-05
17-day-old,7.345378675593928e-05
egg,7.345378675593928e-05
radiographic,7.345378675593928e-05
12.6,7.345378675593928e-05
iodinated,7.345378675593928e-05
midbrain,7.345378675593928e-05
irregular,7.345378675593928e-05
abolish,7.345378675593928e-05
leukopenia,7.345378675593928e-05
persists,7.345378675593928e-05
cells.14,7.345378675593928e-05
angiotensln,7.345378675593928e-05
diminution,7.345378675593928e-05
preclude,7.345378675593928e-05
massively,7.188958980441917e-05
amplifies,7.188958980441917e-05
approx,7.188958980441917e-05
schedules,7.16911111202645e-05
fluoride,7.16911111202645e-05
step,7.16911111202645e-05
incubation,7.16911111202645e-05
-1,7.16911111202645e-05
hct116,7.16911111202645e-05
0.03,7.16911111202645e-05
part,7.16911111202645e-05
mcf7,7.16911111202645e-05
citrate,7.16911111202645e-05
non-human,6.933345553128412e-05
above,6.933345553128412e-05
deleterious,6.927194760553146e-05
differently,6.927194760553146e-05
basal,6.927194760553146e-05
humoral,6.927194760553146e-05
long-acting,6.927194760553146e-05
particles,6.927194760553146e-05
iron-fortified,6.927194760553146e-05
desirable,6.927194760553146e-05
'',6.927194760553146e-05
``,6.927194760553146e-05
25-mg,6.927194760553146e-05
saponins,6.927194760553146e-05
stem-and-leaf,6.927194760553146e-05
ginseng,6.927194760553146e-05
sampling,6.927194760553146e-05
ermbt,6.927194760553146e-05
arteries,6.927194760553146e-05
dietary-obese,6.927194760553146e-05
rabbits,6.927194760553146e-05
3.5,6.927194760553146e-05
renally,6.927194760553146e-05
constant,6.927194760553146e-05
mcf-7,6.927194760553146e-05
aptt,6.927194760553146e-05
tbg,6.927194760553146e-05
dependence,6.927194760553146e-05
hmgcoa,6.927194760553146e-05
circulating,6.927194760553146e-05
serial,6.927194760553146e-05
fasting,6.927194760553146e-05
testing,6.86003006249436e-05
second,6.771838292130017e-05
moreover,6.699386744246638e-05
atypical,6.699386744246638e-05
nad+-dependent,6.699386744246638e-05
too,6.699386744246638e-05
2+,6.699386744246638e-05
postural,6.657705179846651e-05
0.1,6.571676358313461e-05
little,6.559741470624214e-05
dependent,6.277104727359095e-05
divided,6.277104727359095e-05
light,6.277104727359095e-05
tissues,6.274865103983451e-05
mask,6.216876766573787e-05
exogenous,6.216876766573787e-05
occasional,6.216876766573787e-05
approach,6.216876766573787e-05
dopamine-induced,6.216876766573787e-05
achievement,6.216876766573787e-05
0.7,6.216876766573787e-05
restricted,6.216876766573787e-05
implicated,6.216876766573787e-05
long-,6.216876766573787e-05
sex,6.216876766573787e-05
twelve,6.216876766573787e-05
selectively,6.216876766573787e-05
consistent,6.216876766573787e-05
collapse,6.216876766573787e-05
intraperitoneal,6.216876766573787e-05
tended,6.216876766573787e-05
disorders,6.216876766573787e-05
reducing,6.216876766573787e-05
antinociception,6.216876766573787e-05
mrsa,6.216876766573787e-05
abolished,6.216876766573787e-05
implantable,6.106383222093115e-05
requiring,5.985480456671688e-05
sensitizers,5.937456481230896e-05
methicillin-resistant,5.937456481230896e-05
volatile,5.937456481230896e-05
talk,5.937456481230896e-05
optimal,5.937456481230896e-05
antianginal,5.937456481230896e-05
=1,5.937456481230896e-05
g/day,5.937456481230896e-05
hypercholesterolemia,5.937456481230896e-05
hypercholesterolemic,5.937456481230896e-05
noninsulin,5.937456481230896e-05
fifteen,5.937456481230896e-05
2.5-,5.937456481230896e-05
whenever,5.937456481230896e-05
going,5.937456481230896e-05
0.91,5.937456481230896e-05
propatenone,5.937456481230896e-05
antiarrhythrnics,5.937456481230896e-05
seriraline,5.937456481230896e-05
sympatholytic,5.937456481230896e-05
absent,5.937456481230896e-05
pesticide,5.937456481230896e-05
aim,5.937456481230896e-05
rate-limiting,5.937456481230896e-05
442,5.937456481230896e-05
375,5.937456481230896e-05
non-smoking,5.937456481230896e-05
microg/ml,5.937456481230896e-05
new,5.937456481230896e-05
men,5.937456481230896e-05
25-o-desacetyl,5.937456481230896e-05
high-performance,5.937456481230896e-05
antinonciceptive,5.937456481230896e-05
peptides,5.937456481230896e-05
intracisternal,5.937456481230896e-05
paper,5.937456481230896e-05
holed,5.937456481230896e-05
field,5.937456481230896e-05
cellular,5.937456481230896e-05
901,5.937456481230896e-05
457,5.937456481230896e-05
bodyweight,5.937456481230896e-05
appetite,5.937456481230896e-05
respect,5.937456481230896e-05
estrogenic,5.937456481230896e-05
comparative,5.937456481230896e-05
proved,5.937456481230896e-05
28-week,5.937456481230896e-05
sh/fa,5.937456481230896e-05
submitted,5.937456481230896e-05
hydroalcoholic,5.937456481230896e-05
sh/da,5.937456481230896e-05
surfactant,5.937456481230896e-05
r+,5.937456481230896e-05
-enantiomers,5.937456481230896e-05
erectile,5.937456481230896e-05
psoriatic,5.937456481230896e-05
app,5.937456481230896e-05
event,5.937456481230896e-05
l50,5.937456481230896e-05
mcg/,5.937456481230896e-05
us,5.937456481230896e-05
-associated,5.937456481230896e-05
entry,5.937456481230896e-05
0.075,5.937456481230896e-05
proportions,5.937456481230896e-05
distilled,5.937456481230896e-05
fermented,5.937456481230896e-05
0.35,5.937456481230896e-05
desethylzaleplon,5.937456481230896e-05
sum,5.937456481230896e-05
definite,5.937456481230896e-05
benzodiazepines,5.937456481230896e-05
lung,5.937456481230896e-05
bromide,5.937456481230896e-05
rocuronium,5.937456481230896e-05
applicable,5.937456481230896e-05
29-40,5.937456481230896e-05
sequestered,5.937456481230896e-05
-a,5.937456481230896e-05
kappa,5.937456481230896e-05
transiently,5.937456481230896e-05
gonadotropin,5.937456481230896e-05
1.02,5.937456481230896e-05
digoxin/placebo,5.937456481230896e-05
ratios,5.937456481230896e-05
-treated,5.937456481230896e-05
12-week,5.937456481230896e-05
unconjugated,5.937456481230896e-05
fluorescence,5.937456481230896e-05
unmodified,5.937456481230896e-05
polymer/,5.937456481230896e-05
723,5.937456481230896e-05
318,5.937456481230896e-05
unique,5.937456481230896e-05
biopharmaceutical,5.937456481230896e-05
9.9-g/m2,5.937456481230896e-05
permit,5.937456481230896e-05
202.5,5.937456481230896e-05
purification,5.937456481230896e-05
histidines,5.937456481230896e-05
zinc-chelating,5.937456481230896e-05
protocol,5.937456481230896e-05
exploited,5.937456481230896e-05
inhalational,5.937456481230896e-05
76,5.937456481230896e-05
warfarin-like,5.937456481230896e-05
occurrences,5.937456481230896e-05
-blockers,5.937456481230896e-05
mao-is,5.937456481230896e-05
fexofenadine,5.937456481230896e-05
acids,5.937456481230896e-05
digestion,5.937456481230896e-05
labelled,5.937456481230896e-05
0.125,5.937456481230896e-05
childbearing,5.937456481230896e-05
slow-release,5.937456481230896e-05
p-glycoprotein-mediated,5.937456481230896e-05
cyp3a5,5.937456481230896e-05
subgroup,5.937456481230896e-05
i.e,5.937456481230896e-05
nmda,5.937456481230896e-05
sigma-2,5.937456481230896e-05
5-ht,5.937456481230896e-05
affinities,5.937456481230896e-05
adefovir,5.937456481230896e-05
fractions,5.937456481230896e-05
perchlorate,5.937456481230896e-05
scale,5.937456481230896e-05
dose-time,5.937456481230896e-05
250-mg,5.937456481230896e-05
empiric,5.937456481230896e-05
2.0,5.937456481230896e-05
interest,5.937456481230896e-05
m.c,5.937456481230896e-05
blot,5.937456481230896e-05
prefrontal,5.937456481230896e-05
statin,5.937456481230896e-05
tightly,5.937456481230896e-05
embolism,5.937456481230896e-05
dipivoxil,5.937456481230896e-05
heparins,5.937456481230896e-05
fixed-interval,5.937456481230896e-05
squirrel,5.937456481230896e-05
fixed-ratio,5.937456481230896e-05
age,5.937456481230896e-05
colorectal,5.937456481230896e-05
irinotecan/5-fu/leucovorin,5.937456481230896e-05
1.00,5.937456481230896e-05
0.94,5.937456481230896e-05
1.14,5.937456481230896e-05
1.10,5.937456481230896e-05
1.09,5.937456481230896e-05
1.04,5.937456481230896e-05
0-infinity,5.937456481230896e-05
geometric,5.937456481230896e-05
absolute,5.937456481230896e-05
hydroxides,5.937456481230896e-05
formally,5.937456481230896e-05
comparatively,5.937456481230896e-05
resistances,5.937456481230896e-05
whole-cell,5.937456481230896e-05
inositol,5.937456481230896e-05
patch-clamp,5.937456481230896e-05
disintegrins,5.937456481230896e-05
homodimeric,5.937456481230896e-05
monomeric,5.937456481230896e-05
disintegrin,5.937456481230896e-05
northern,5.937456481230896e-05
rna,5.937456481230896e-05
varying,5.937456481230896e-05
organogenesis,5.937456481230896e-05
"1,4,5-trisphosphate",5.937456481230896e-05
microfluorometry,5.937456481230896e-05
recording,5.937456481230896e-05
acquired,5.937456481230896e-05
congenital,5.937456481230896e-05
myeloma,5.937456481230896e-05
relapsed,5.937456481230896e-05
lenalidomide-cci-779,5.937456481230896e-05
anti,5.937456481230896e-05
i.,5.937456481230896e-05
neurotoxin,5.937456481230896e-05
ruthenium,5.937456481230896e-05
cessation,5.937456481230896e-05
dramatically,5.937456481230896e-05
49.1,5.937456481230896e-05
16.6,5.937456481230896e-05
fura-2,5.937456481230896e-05
xenograft-bearing,5.911787904577803e-05
0.75,5.911787904577803e-05
ruled,5.911787904577803e-05
toxin,5.911787904577803e-05
prophylactic,5.911787904577803e-05
vasoactive,5.911787904577803e-05
attention,5.911787904577803e-05
0.62,5.911787904577803e-05
digit,5.911787904577803e-05
0.53,5.911787904577803e-05
symbol,5.911787904577803e-05
.014,5.911787904577803e-05
cns-impairing,5.911787904577803e-05
0.44,5.911787904577803e-05
spent,5.911787904577803e-05
balance,5.911787904577803e-05
substitution,5.911787904577803e-05
zone,5.911787904577803e-05
application,5.911787904577803e-05
0.28,5.911787904577803e-05
pr,5.911787904577803e-05
dpcpx-induced,5.911787904577803e-05
theophylline-induced,5.911787904577803e-05
cm3,5.911787904577803e-05
b3,5.911787904577803e-05
aureus,5.911787904577803e-05
0.81,5.911787904577803e-05
short-acting,5.911787904577803e-05
competitive,5.911787904577803e-05
copying,5.911787904577803e-05
subsequent,5.761621345812262e-05
9,5.725232207065556e-05
pronounced,5.703907976795097e-05
buspirone,5.703907976795097e-05
weak,5.6314357804509996e-05
melanoma,5.6314357804509996e-05
injected,5.6314357804509996e-05
a375,5.6314357804509996e-05
neuronal,5.6314357804509996e-05
glutamate,5.6314357804509996e-05
metabotropic,5.6314357804509996e-05
extracellular,5.6314357804509996e-05
plate,5.616156290288998e-05
schedule,5.616156290288998e-05
suppressed,5.616156290288998e-05
chickens,5.616156290288998e-05
applied,5.616156290288998e-05
review,5.616156290288998e-05
staphylococcus,5.616156290288998e-05
dysfunction,5.616156290288998e-05
contraction,5.616156290288998e-05
times,5.458444419403907e-05
distinct,5.407742892959977e-05
shortly,5.407742892959977e-05
tolerance,5.407742892959977e-05
locomotion,5.407742892959977e-05
necessitate,5.407742892959977e-05
alcoholic,5.407742892959977e-05
beverages,5.407742892959977e-05
megakaryocytes,5.407742892959977e-05
resistant,5.407742892959977e-05
mild,5.3719911434546574e-05
hypoprothrombinemic,5.365869710072246e-05
neutropenic,5.365869710072246e-05
neurotoxicity,5.365869710072246e-05
minus,5.365869710072246e-05
thiazide-like,5.365869710072246e-05
none,5.365869710072246e-05
normovolemic,5.365869710072246e-05
iv/im,5.365869710072246e-05
a1-selective,5.365869710072246e-05
a2-selective,5.365869710072246e-05
suxamethonium,5.365869710072246e-05
length,5.365869710072246e-05
0.70,5.365869710072246e-05
establish,5.365869710072246e-05
committed,5.365869710072246e-05
attempt,5.365869710072246e-05
causation,5.365869710072246e-05
immunocompromised,5.365869710072246e-05
drug/drug,5.365869710072246e-05
vaccinations,5.365869710072246e-05
haemorrhagic,5.365869710072246e-05
organism,5.365869710072246e-05
experiment,5.365869710072246e-05
neuropsychiatric,5.365869710072246e-05
"1,3-difluoro-2-propanol-intoxicated",5.365869710072246e-05
reversal,5.365869710072246e-05
diflunisal/acetaminophen,5.365869710072246e-05
limits,5.365869710072246e-05
nonlethal,5.365869710072246e-05
ineffective,5.365869710072246e-05
cyclic,5.365869710072246e-05
antidotal,5.365869710072246e-05
eliminate,5.365869710072246e-05
restriction,5.365869710072246e-05
precipitous,5.365869710072246e-05
inactivation,5.365869710072246e-05
ulceration,5.365869710072246e-05
derive,5.365869710072246e-05
microalbuminuria,5.365869710072246e-05
ea,5.365869710072246e-05
6.25,5.365869710072246e-05
capacity,5.3116819904830415e-05
presentation,5.3116819904830415e-05
reviewed,5.3116819904830415e-05
5.5,5.3116819904830415e-05
ai,5.3116819904830415e-05
open,5.3116819904830415e-05
analogue,5.3116819904830415e-05
concerning,5.3116819904830415e-05
receptors,5.3116819904830415e-05
attenuation,5.3116819904830415e-05
tiva,5.3116819904830415e-05
edema,5.3116819904830415e-05
contrast,5.3116819904830415e-05
prevention,5.3116819904830415e-05
accentuate,5.3116819904830415e-05
pcp-induced,5.3116819904830415e-05
gain,5.3116819904830415e-05
identify,5.3116819904830415e-05
prostacyclin,5.300170122946035e-05
cyclosporine-induced,5.300170122946035e-05
calcium-containing,4.947764551765932e-05
discrimination,4.947764551765932e-05
1-year,4.947764551765932e-05
fraction,4.947764551765932e-05
genetically,4.947764551765932e-05
lean,4.947764551765932e-05
ulcerans,4.947764551765932e-05
generation,4.947764551765932e-05
far,4.947764551765932e-05
infant,4.947764551765932e-05
randomly,4.947764551765932e-05
monthly,4.947764551765932e-05
evoked,4.947764551765932e-05
uptake-1,4.947764551765932e-05
impairment,4.889555926945732e-05
chelating,4.814384142470818e-05
edetate,4.814384142470818e-05
disodium,4.814384142470818e-05
degrees,4.814384142470818e-05
12.5,4.783894876214667e-05
overall,4.783894876214667e-05
d.h.e,4.6298552781154356e-05
dihydroergotamine,4.6298552781154356e-05
accompanied,4.485455224512158e-05
gram,4.485455224512158e-05
marked,4.295448443869532e-05
hepatitis,4.2831303418644495e-05
per,4.281432202590807e-05
formed,4.185166632642012e-05
transporter,4.185166632642012e-05
variability,4.174725950978342e-05
much,4.174725950978342e-05
v,3.9581189677839745e-05
support,3.9581189677839745e-05
globulin,3.9581189677839745e-05
psychoses,3.9581189677839745e-05
designed,3.9581189677839745e-05
physiological,3.9581189677839745e-05
volunteer,3.9581189677839745e-05
micromol/l,3.9581189677839745e-05
micrograms/ml,3.9581189677839745e-05
improvements,3.9581189677839745e-05
allograft,3.9581189677839745e-05
formula,3.9581189677839745e-05
young,3.9581189677839745e-05
greatly,3.9581189677839745e-05
mycobacterium,3.9581189677839745e-05
subjective,3.9581189677839745e-05
extract,3.9581189677839745e-05
novo,3.9581189677839745e-05
pyrocarbonate,3.9581189677839745e-05
drl,3.9581189677839745e-05
surgery,3.9581189677839745e-05
compatibility,3.9581189677839745e-05
systemically,3.9581189677839745e-05
resemble,3.9581189677839745e-05
year,3.9581189677839745e-05
assigned,3.9581189677839745e-05
proven,3.9581189677839745e-05
nonclinical,3.9581189677839745e-05
allow,3.9581189677839745e-05
cyp2e1,3.9581189677839745e-05
uncontrolled,3.9581189677839745e-05
cumulative,3.9581189677839745e-05
times/day,3.9581189677839745e-05
kidneys,3.9581189677839745e-05
drawn,3.9581189677839745e-05
morning,3.9581189677839745e-05
polyene,3.9581189677839745e-05
syringe,3.9581189677839745e-05
value,3.9581189677839745e-05
2c9,3.9581189677839745e-05
regulation,3.9581189677839745e-05
prospective,3.9581189677839745e-05
osteoporosis,3.9581189677839745e-05
seen,3.6611226219784854e-05
cups,2.968519724988461e-05
15.0,2.968519724988461e-05
iron/6,2.968519724988461e-05
breakfast,2.968519724988461e-05
cereals,2.968519724988461e-05
5-35,2.968519724988461e-05
clo-4-,2.968519724988461e-05
kit,2.968519724988461e-05
tab,2.968519724988461e-05
ria,2.968519724988461e-05
digi-,2.968519724988461e-05
inn,2.968519724988461e-05
recorded,2.968519724988461e-05
nerally,2.968519724988461e-05
assumed,2.968519724988461e-05
ge,2.968519724988461e-05
transplantation,2.968519724988461e-05
oz,2.968519724988461e-05
employing,2.968519724988461e-05
fetal,2.968519724988461e-05
hrs,2.968519724988461e-05
ten,2.968519724988461e-05
1-866-263-8483,2.968519724988461e-05
123,2.968519724988461e-05
beta-receptor,2.968519724988461e-05
registry,2.968519724988461e-05
ameliorate,2.968519724988461e-05
potentials,2.968519724988461e-05
sessions,2.968519724988461e-05
relaxation,2.968519724988461e-05
preconstricted,2.968519724988461e-05
puncture,2.968519724988461e-05
mmol/l,2.968519724988461e-05
systematic,2.968519724988461e-05
hydrolysis,2.968519724988461e-05
yeast,2.968519724988461e-05
person,2.968519724988461e-05
endoscopic,2.968519724988461e-05
gastroduodenal,2.968519724988461e-05
coated,2.968519724988461e-05
oa,2.968519724988461e-05
antiaddictive,2.968519724988461e-05
2400,2.968519724988461e-05
actively,2.968519724988461e-05
endoscopy,2.968519724988461e-05
thyroxine-binding,2.968519724988461e-05
aqueous,2.968519724988461e-05
equilibration,2.968519724988461e-05
tend,2.968519724988461e-05
tdm,2.968519724988461e-05
ultracentrifugation,2.968519724988461e-05
thrombolytic,2.968519724988461e-05
1-866-amevive,2.968519724988461e-05
encouraged,2.968519724988461e-05
coffee,2.968519724988461e-05
biogen,2.968519724988461e-05
ulcers,2.968519724988461e-05
consisting,2.968519724988461e-05
iu/ml,2.968519724988461e-05
microgram/ml,2.968519724988461e-05
medium,2.968519724988461e-05
3.7,2.968519724988461e-05
replaced,2.968519724988461e-05
defined,2.968519724988461e-05
proliferates,2.968519724988461e-05
confirm,2.968519724988461e-05
unfractionated,2.968519724988461e-05
dopamine2-,2.968519724988461e-05
serotonin2-receptors,2.968519724988461e-05
underlies,2.968519724988461e-05
units/day,2.968519724988461e-05
lithium-a,2.968519724988461e-05
habituation,2.968519724988461e-05
habituating,2.968519724988461e-05
addictive,2.968519724988461e-05
producing,2.968519724988461e-05
6-mg,2.968519724988461e-05
episode,2.968519724988461e-05
calling,2.968519724988461e-05
providers,2.968519724988461e-05
provides,2.968519724988461e-05
adjuvants,2.968519724988461e-05
organs,2.968519724988461e-05
transferase,2.968519724988461e-05
predominant,2.968519724988461e-05
pregnant,2.968519724988461e-05
"15,000",2.968519724988461e-05
4-hour,2.968519724988461e-05
recur,2.968519724988461e-05
blind,2.968519724988461e-05
cross-over,2.968519724988461e-05
lactulose,2.968519724988461e-05
binding-based,2.968519724988461e-05
routinely,2.968519724988461e-05
concentration-dependent,2.968519724988461e-05
american,2.968519724988461e-05
hundred,2.968519724988461e-05
enantiomer,2.968519724988461e-05
diethyl,2.968519724988461e-05
synthesis-inhibiting,2.968519724988461e-05
75-mg,2.968519724988461e-05
swine,2.968519724988461e-05
toradoliv/im,2.968519724988461e-05
tranexamic,2.968519724988461e-05
aminocaproic,2.968519724988461e-05
concentrating,2.968519724988461e-05
mglur,2.968519724988461e-05
treating,2.968519724988461e-05
antifibrinolytic,2.968519724988461e-05
a-chloralose,2.968519724988461e-05
udp-glucuronyl,2.968519724988461e-05
last,2.968519724988461e-05
anesthetized,2.968519724988461e-05
enroll,2.968519724988461e-05
aimed,2.968519724988461e-05
rationalized,2.968519724988461e-05
lunch,2.968519724988461e-05
meaningfully,2.968519724988461e-05
comparisons,2.968519724988461e-05
historical,2.968519724988461e-05
six-healthy-male,2.968519724988461e-05
9.93,2.968519724988461e-05
48.59,2.968519724988461e-05
levofloxacin/oxycodone,2.968519724988461e-05
document,2.968519724988461e-05
recommend,2.968519724988461e-05
7.73,2.968519724988461e-05
2.6,2.968519724988461e-05
2000,2.968519724988461e-05
8.52,2.968519724988461e-05
succinylcholine-facilitated,2.968519724988461e-05
mixture,2.968519724988461e-05
tracheal,2.968519724988461e-05
intubation,2.968519724988461e-05
intoxication,2.968519724988461e-05
30.7,2.968519724988461e-05
28.9,2.968519724988461e-05
22.0,2.968519724988461e-05
uncertain,2.968519724988461e-05
excreted,2.968519724988461e-05
49.9,2.968519724988461e-05
1.8,2.968519724988461e-05
immobilised,2.968519724988461e-05
45.7,2.968519724988461e-05
harmonic,2.968519724988461e-05
microg/kg,2.968519724988461e-05
fo,2.968519724988461e-05
7.4,2.968519724988461e-05
m/m,2.968519724988461e-05
7.3,2.968519724988461e-05
aeruginosa,2.968519724988461e-05
pseudomonas,2.968519724988461e-05
"1,25-dihydroxycholecalciferol",2.968519724988461e-05
1.6,2.968519724988461e-05
aspirin/nonsteroidal,2.968519724988461e-05
homocysteine,2.968519724988461e-05
precipitation,2.968519724988461e-05
parameter,2.968519724988461e-05
p450-based,2.968519724988461e-05
r-,2.968519724988461e-05
21.7,2.968519724988461e-05
3500,2.968519724988461e-05
anti-peptic,2.968519724988461e-05
enrolled,2.968519724988461e-05
maintaining,2.968519724988461e-05
1.1,2.968519724988461e-05
hexamethylenimine,2.968519724988461e-05
2-adamantyl,2.968519724988461e-05
rt-pa,2.968519724988461e-05
glycemia,2.968519724988461e-05
indanedione,2.968519724988461e-05
interferences,2.968519724988461e-05
spectrophotometrically,2.968519724988461e-05
red-orange,2.968519724988461e-05
routes,2.968519724988461e-05
clinically-,2.968519724988461e-05
next,2.968519724988461e-05
nursing,2.968519724988461e-05
mono-oxidases,2.968519724988461e-05
monooxygenase,2.968519724988461e-05
fenofibric,2.968519724988461e-05
compassionate,2.968519724988461e-05
rr,2.968519724988461e-05
8-fold,2.968519724988461e-05
cyp-450,2.968519724988461e-05
6-,2.968519724988461e-05
non-specific,2.968519724988461e-05
alpha-,2.968519724988461e-05
2c19,2.968519724988461e-05
ectopy,2.968519724988461e-05
mixed-function,2.968519724988461e-05
dropped,2.968519724988461e-05
androgen,2.968519724988461e-05
30-40,2.968519724988461e-05
water-miscible,2.968519724988461e-05
supplementation,2.968519724988461e-05
contribution,2.968519724988461e-05
microflora,2.968519724988461e-05
sterilize,2.968519724988461e-05
antibiotics-broad-spectrum,2.968519724988461e-05
escherichia,2.968519724988461e-05
coli,2.968519724988461e-05
anti-parkinsonian,2.968519724988461e-05
cohorts,2.968519724988461e-05
calcineurin,2.968519724988461e-05
nonmatched,2.968519724988461e-05
stronger,2.968519724988461e-05
implies,2.968519724988461e-05
posed,2.968519724988461e-05
two-lever,2.968519724988461e-05
signalled-unsignalled,2.968519724988461e-05
differential-reinforcement-of-low-rates,2.968519724988461e-05
lethal,2.968519724988461e-05
alcohol-related,2.968519724988461e-05
alkaline,2.968519724988461e-05
inhibitor-free,2.968519724988461e-05
august,2.968519724988461e-05
program,2.968519724988461e-05
editorials,2.968519724988461e-05
pharmaceutical,2.968519724988461e-05
prostatectomy,2.968519724988461e-05
mellitus,2.968519724988461e-05
wthionamide,2.968519724988461e-05
medline,2.968519724988461e-05
thrombocyte,2.968519724988461e-05
'seroquel,2.968519724988461e-05
newly,2.968519724988461e-05
exhibiting,2.968519724988461e-05
tcaplasma,2.968519724988461e-05
21-day,2.968519724988461e-05
investigations,2.968519724988461e-05
43.4,2.968519724988461e-05
introduced,2.968519724988461e-05
quetiapine,2.968519724988461e-05
captopril-digoxin,2.968519724988461e-05
crystalline,2.968519724988461e-05
zinc,2.968519724988461e-05
anti-asthma,2.968519724988461e-05
january,2.968519724988461e-05
broadly,2.968519724988461e-05
',2.968519724988461e-05
tartrate,2.968519724988461e-05
esterases,2.968519724988461e-05
multicenter,2.968519724988461e-05
1:1:1,2.968519724988461e-05
101,2.968519724988461e-05
characterize,2.968519724988461e-05
alpha-2,2.968519724988461e-05
preventing,2.968519724988461e-05
characteristic,2.968519724988461e-05
0.375,2.968519724988461e-05
reflecting,2.968519724988461e-05
pointes-type,2.968519724988461e-05
balanced,2.968519724988461e-05
qhs,2.968519724988461e-05
terms,2.968519724988461e-05
searches,2.968519724988461e-05
1999,2.968519724988461e-05
abstracts,2.968519724988461e-05
commentaries,2.968519724988461e-05
premedline,2.968519724988461e-05
150-mg,2.968519724988461e-05
collected,2.968519724988461e-05
2-3,2.968519724988461e-05
display,2.968519724988461e-05
lag,2.968519724988461e-05
n=180,2.968519724988461e-05
relapses,2.968519724988461e-05
pectoris,2.968519724988461e-05
7-day,2.968519724988461e-05
"1,200",2.968519724988461e-05
delta,2.968519724988461e-05
extrarenal,2.968519724988461e-05
activated,2.968519724988461e-05
oxidized,2.968519724988461e-05
irbesartan,2.968519724988461e-05
substrates/inhibitors,2.968519724988461e-05
quality,2.968519724988461e-05
528,2.968519724988461e-05
erythromycin,2.968519724988461e-05
washout,2.968519724988461e-05
unaltered,2.968519724988461e-05
ocular,2.968519724988461e-05
haemodynamic,2.968519724988461e-05
aldosterone,2.968519724988461e-05
kappa-selective,2.968519724988461e-05
mu-,2.968519724988461e-05
hyperpolarized,2.968519724988461e-05
opioids,2.968519724988461e-05
873,2.968519724988461e-05
12-month,2.968519724988461e-05
superiority,2.968519724988461e-05
option,2.968519724988461e-05
first-line,2.968519724988461e-05
choice,2.968519724988461e-05
biochemical,2.968519724988461e-05
ingredient,2.968519724988461e-05
metab-olizers,2.968519724988461e-05
colon,2.968519724988461e-05
line,2.968519724988461e-05
pro-oxidant,2.968519724988461e-05
alkyating,2.968519724988461e-05
superior,2.968519724988461e-05
source,2.968519724988461e-05
pumps,2.968519724988461e-05
early-phase,2.968519724988461e-05
extrapyramidal,2.968519724988461e-05
hyperprolactinaemia,2.968519724988461e-05
agranulocytosis,2.968519724988461e-05
external,2.968519724988461e-05
diluent,2.968519724988461e-05
margin,2.968519724988461e-05
bar-press,2.968519724988461e-05
derivative,2.968519724988461e-05
thienobenzodiazepine,2.968519724988461e-05
manufacturers,2.968519724988461e-05
meclofenamate,2.2020344011774995e-05
carcinogenicity,1.9789668189607035e-05
carcinogenesis,1.9789668189607035e-05
104-week,1.9789668189607035e-05
fertility,1.9789668189607035e-05
factor,1.9789668189607035e-05
older,1.9789668189607035e-05
candida,1.9789668189607035e-05
respiration,1.9789668189607035e-05
psychostimulant,1.9789668189607035e-05
measuring,1.9789668189607035e-05
vas,1.9789668189607035e-05
deferens,1.9789668189607035e-05
guinea-pig,1.9789668189607035e-05
again,1.9789668189607035e-05
linked,1.9789668189607035e-05
intramuscularly,1.9789668189607035e-05
concentrates,1.9789668189607035e-05
hospitalized,1.9789668189607035e-05
appreciably,1.9789668189607035e-05
substituted,1.9789668189607035e-05
psa,1.9789668189607035e-05
acquisition,1.9789668189607035e-05
fasted,1.9789668189607035e-05
mucosal,1.9789668189607035e-05
spectrum,1.9789668189607035e-05
cyclooxygenase-2,1.9789668189607035e-05
neutralized,1.9789668189607035e-05
bred,1.9789668189607035e-05
non-diabetic,1.9789668189607035e-05
measure,1.9789668189607035e-05
8-week,1.9789668189607035e-05
verified,1.9789668189607035e-05
antibodies,1.9789668189607035e-05
stroke,1.9789668189607035e-05
rapidly,1.9789668189607035e-05
relationships,1.9789668189607035e-05
isoforms,1.9789668189607035e-05
costs,1.9789668189607035e-05
table,1.9789668189607035e-05
histidine,1.9789668189607035e-05
prepared,1.9789668189607035e-05
residues,1.9789668189607035e-05
o11,1.9789668189607035e-05
wide,1.9789668189607035e-05
serotype,1.9789668189607035e-05
pathways,1.9789668189607035e-05
depth,1.9789668189607035e-05
create,1.9789668189607035e-05
hydrolase,1.9789668189607035e-05
coombs,1.9789668189607035e-05
parathyroid,1.9789668189607035e-05
gene,1.9789668189607035e-05
drug-metabolizing,1.9789668189607035e-05
determination,1.9789668189607035e-05
authors,1.9789668189607035e-05
immunoreactive,1.9789668189607035e-05
endothelial,1.9789668189607035e-05
65,1.9789668189607035e-05
aerobic,9.89460245404139e-06
mortality,9.89460245404139e-06
estimated,9.89460245404139e-06
bilirubin,9.89460245404139e-06
arrest,9.89460245404139e-06
focus,9.89460245404139e-06
advantages,9.89460245404139e-06
work,9.89460245404139e-06
full,9.89460245404139e-06
pra,9.89460245404139e-06
progestogen,9.89460245404139e-06
allergic,9.89460245404139e-06
cardiopulmonary,9.89460245404139e-06
n=17,9.89460245404139e-06
affects,9.89460245404139e-06
ontario,9.89460245404139e-06
alcoholics,9.89460245404139e-06
maximize,9.89460245404139e-06
summarized,9.89460245404139e-06
levonorgestrel-treated,9.89460245404139e-06
left,9.89460245404139e-06
1602,9.89460245404139e-06
shock,9.89460245404139e-06
lethality,9.89460245404139e-06
salicylates-salicylates,9.89460245404139e-06
sample,9.89460245404139e-06
insignificant,9.89460245404139e-06
predict,9.89460245404139e-06
mimicked,9.89460245404139e-06
assessments,9.89460245404139e-06
obstruction,9.89460245404139e-06
manifested,9.89460245404139e-06
duloxetine-treated,9.89460245404139e-06
conclusions/interpretation,9.89460245404139e-06
aims/hypothesis,9.89460245404139e-06
offered,9.89460245404139e-06
compatible,9.89460245404139e-06
readings,9.89460245404139e-06
sulfosalicylic,9.89460245404139e-06
ec50,9.89460245404139e-06
ames,9.89460245404139e-06
dipstick,9.89460245404139e-06
sg,9.89460245404139e-06
n-multistix,9.89460245404139e-06
likewise,9.89460245404139e-06
diffusible,9.89460245404139e-06
strand,9.89460245404139e-06
recommendations,9.89460245404139e-06
size,9.89460245404139e-06
cysteine,9.89460245404139e-06
trimethyl,9.89460245404139e-06
failing,9.89460245404139e-06
17.0,9.89460245404139e-06
domestic,9.89460245404139e-06
density,9.89460245404139e-06
8.0,9.89460245404139e-06
mg/kg/ml,9.89460245404139e-06
radioligand,9.89460245404139e-06
hydrogen-3,9.89460245404139e-06
2946,9.89460245404139e-06
62,9.89460245404139e-06
defect,9.89460245404139e-06
supplements/antacids,9.89460245404139e-06
carrier,9.89460245404139e-06
"10,11-epoxide",9.89460245404139e-06
numbers,9.89460245404139e-06
respond,9.89460245404139e-06
aged,9.89460245404139e-06
younger,9.89460245404139e-06
contains,9.89460245404139e-06
cox-2,9.89460245404139e-06
permeability,9.89460245404139e-06
preventive,9.89460245404139e-06
nonopioid,9.89460245404139e-06
mutagenic,9.89460245404139e-06
genotoxic,9.89460245404139e-06
infants,9.89460245404139e-06
discontinue,9.89460245404139e-06
decision,9.89460245404139e-06
mothers,9.89460245404139e-06
teratogenic,9.89460245404139e-06
reinfarction,9.89460245404139e-06
interferons,9.89460245404139e-06
embryocidal,9.89460245404139e-06
mi,9.89460245404139e-06
just,9.89460245404139e-06
failures,9.89460245404139e-06
alpha,9.89460245404139e-06
hence,9.89460245404139e-06
6-deoxy,9.89460245404139e-06
pgp,9.89460245404139e-06
undergoes,9.89460245404139e-06
66,9.89460245404139e-06
trans-diol,9.89460245404139e-06
tea,9.89460245404139e-06
glucocorticoid-induced,9.89460245404139e-06
pass,9.89460245404139e-06
450,9.89460245404139e-06
estrogen-dependent,9.89460245404139e-06
signalling,9.89460245404139e-06
emphasize,9.89460245404139e-06
disruption,9.89460245404139e-06
vitamin-d-mediated,9.89460245404139e-06
polyphenols,9.89460245404139e-06
ascertain,9.89460245404139e-06
900,9.89460245404139e-06
1mg,9.89460245404139e-06
10-63,9.89460245404139e-06
streptozotocin-induced,9.89460245404139e-06
estimation,9.89460245404139e-06
behaviors,9.89460245404139e-06
task,9.89460245404139e-06
training,9.89460245404139e-06
flu-like,9.89460245404139e-06
distinctive,9.89460245404139e-06
psychotomimetic,9.89460245404139e-06
septic,9.89460245404139e-06
aminoglycosidic,9.89460245404139e-06
menopause,9.89460245404139e-06
always,9.89460245404139e-06
flushes,9.89460245404139e-06
ganoderma,9.89460245404139e-06
multidrug-resistant,9.89460245404139e-06
interresponse,9.89460245404139e-06
p-,9.89460245404139e-06
antidepressant-warfarin,9.89460245404139e-06
violations,9.89460245404139e-06
c57bl/6,9.89460245404139e-06
mptp-evoked,9.89460245404139e-06
antiglaucoma,9.89460245404139e-06
miconazole,9.89460245404139e-06
nitrate,9.89460245404139e-06
albicans,9.89460245404139e-06
investigation,9.89460245404139e-06
contributed,9.89460245404139e-06
person-years,9.89460245404139e-06
"430,455",9.89460245404139e-06
"407,370",9.89460245404139e-06
sought,9.89460245404139e-06
antistress,9.89460245404139e-06
titers,9.89460245404139e-06
monoclonal,9.89460245404139e-06
haca,9.89460245404139e-06
deletion,9.89460245404139e-06
mutagenesis,9.89460245404139e-06
viii,9.89460245404139e-06
ix,9.89460245404139e-06
xi,9.89460245404139e-06
one-stage,9.89460245404139e-06
accordance,9.89460245404139e-06
non-enzyme,9.89460245404139e-06
limb,9.89460245404139e-06
switched,9.89460245404139e-06
fischer-344,9.89460245404139e-06
stereotyped,9.89460245404139e-06
96,9.89460245404139e-06
gentamycin/kg,9.89460245404139e-06
bwt,9.89460245404139e-06
i.v,9.89460245404139e-06
extensor,9.89460245404139e-06
hind,9.89460245404139e-06
digital,9.89460245404139e-06
help,9.89460245404139e-06
gavage,9.89460245404139e-06
thought,9.89460245404139e-06
conventional,9.89460245404139e-06
clinistix,9.89460245404139e-06
benedicts,9.89460245404139e-06
resecting,9.89460245404139e-06
cecum,9.89460245404139e-06
ileocecal,9.89460245404139e-06
succinylcholine-induced,9.89460245404139e-06
depletor,9.89460245404139e-06
esmolol,9.89460245404139e-06
~20,9.89460245404139e-06
situ,9.89460245404139e-06
declining,9.89460245404139e-06
lumen,9.89460245404139e-06
essentially,9.89460245404139e-06
80-95,9.89460245404139e-06
ligated,9.89460245404139e-06
logarithmic,9.89460245404139e-06
jaff,9.89460245404139e-06
~7,9.89460245404139e-06
females,9.89460245404139e-06
trace,9.89460245404139e-06
genotypes,9.89460245404139e-06
ataxia,9.89460245404139e-06
felodipine,9.89460245404139e-06
s.c,9.89460245404139e-06
intraluminally,9.89460245404139e-06
transit-enhancing,9.89460245404139e-06
disturbing,9.89460245404139e-06
presented,9.89460245404139e-06
k-dependent,9.89460245404139e-06
reproductive,9.89460245404139e-06
ex,9.89460245404139e-06
txb2,9.89460245404139e-06
anti-platelet,9.89460245404139e-06
often,9.89460245404139e-06
antidiuretic,9.89460245404139e-06
tobacco,9.89460245404139e-06
quantitative,9.89460245404139e-06
impulsivity,9.89460245404139e-06
seeking,9.89460245404139e-06
user,9.89460245404139e-06
substitute,9.89460245404139e-06
extra,9.89460245404139e-06
ribs,9.89460245404139e-06
thoracic,9.89460245404139e-06
existing,9.89460245404139e-06
smallest,9.89460245404139e-06
rodent,9.89460245404139e-06
cortisol,9.89460245404139e-06
within-subject,9.89460245404139e-06
four-session,9.89460245404139e-06
enterococcus,9.89460245404139e-06
homozygous,9.89460245404139e-06
"3,7-dihydroxyflavone",9.89460245404139e-06
faecalis,9.89460245404139e-06
vancomycin-sensitive,9.89460245404139e-06
tension,9.89460245404139e-06
cigarettes,9.89460245404139e-06
encountered,9.89460245404139e-06
intensified,9.89460245404139e-06
phenotype,9.89460245404139e-06
alleles,9.89460245404139e-06
1/,9.89460245404139e-06
faecium,9.89460245404139e-06
lucidum,9.89460245404139e-06
dexmedetomidine-induced,9.89460245404139e-06
correlated,9.89460245404139e-06
3:1,9.89460245404139e-06
ration,9.89460245404139e-06
potency,9.89460245404139e-06
n-demethylated,9.89460245404139e-06
opioid-dependent,9.89460245404139e-06
cascade,9.89460245404139e-06
cream,9.89460245404139e-06
dried,9.89460245404139e-06
characterization,9.89460245404139e-06
generated,9.89460245404139e-06
temporal,9.89460245404139e-06
.82,9.89460245404139e-06
context,9.89460245404139e-06
anova,9.89460245404139e-06
variables,9.89460245404139e-06
alternatively,9.89460245404139e-06
0.1-0.4,9.89460245404139e-06
impinger,9.89460245404139e-06
manufacturer,9.89460245404139e-06
fda,9.89460245404139e-06
tolerant,9.89460245404139e-06
thiol,9.89460245404139e-06
mtt,9.89460245404139e-06
breaks,9.89460245404139e-06
radiolabeled,9.89460245404139e-06
coexisting,9.89460245404139e-06
contents,9.89460245404139e-06
end-stage,9.89460245404139e-06
stock,9.89460245404139e-06
equal,9.89460245404139e-06
sc,9.89460245404139e-06
thirty,9.89460245404139e-06
otherwise,9.89460245404139e-06
metabolizes,9.89460245404139e-06
156,9.89460245404139e-06
187,9.89460245404139e-06
comet,9.89460245404139e-06
hy-per-parathyroidism,9.89460245404139e-06
v/v,9.89460245404139e-06
cefotaxime,9.89460245404139e-06
transfer,9.89460245404139e-06
declines,9.89460245404139e-06
duodenum,9.89460245404139e-06
share,9.89460245404139e-06
longitudinal,9.89460245404139e-06
radiotherapy,9.89460245404139e-06
cardioselective,9.89460245404139e-06
beta-blocker,9.89460245404139e-06
0.012,9.89460245404139e-06
difficulty,9.89460245404139e-06
narrower,9.89460245404139e-06
triazo,9.89460245404139e-06
lam,9.89460245404139e-06
linear,9.89460245404139e-06
transferred,9.89460245404139e-06
remains,9.89460245404139e-06
morphine-experienced,9.89460245404139e-06
stereotypic,9.89460245404139e-06
butenafine,9.89460245404139e-06
achieving,9.89460245404139e-06
0.1-0.8,9.89460245404139e-06
singly,9.89460245404139e-06
accounts,9.89460245404139e-06
copper,9.89460245404139e-06
clinitest,9.89460245404139e-06
strip,9.89460245404139e-06
fehlings,9.89460245404139e-06
exposure-response,9.89460245404139e-06
assessment,9.89460245404139e-06
post-transplant,9.89460245404139e-06
successfully,9.89460245404139e-06
.76,9.89460245404139e-06
.13,9.89460245404139e-06
dodecyl,9.89460245404139e-06
solubilization,9.89460245404139e-06
equilibrium,9.89460245404139e-06
impactor,9.89460245404139e-06
unlike,9.89460245404139e-06
nondrug,9.89460245404139e-06
reinforcer,9.89460245404139e-06
undesirable,9.89460245404139e-06
patterns,9.89460245404139e-06
antigen,9.89460245404139e-06
cyp-2c19,9.89460245404139e-06
3a4/5,9.89460245404139e-06
cyp3a4/5,9.89460245404139e-06
exception,9.89460245404139e-06
cyp4a9,9.89460245404139e-06
documenting,9.89460245404139e-06
14-57,9.89460245404139e-06
purpura,9.89460245404139e-06
survival,9.89460245404139e-06
continuous,9.89460245404139e-06
immunoanalytical,9.89460245404139e-06
24.7,9.89460245404139e-06
prophylaxis,9.89460245404139e-06
sub-g1,9.89460245404139e-06
22.4,9.89460245404139e-06
dasatinib-,9.89460245404139e-06
20.1,9.89460245404139e-06
emergence,9.89460245404139e-06
sterol,9.89460245404139e-06
thrombopenia,9.89460245404139e-06
3.2,9.89460245404139e-06
8.5,9.89460245404139e-06
3.4,9.89460245404139e-06
reactive,9.89460245404139e-06
phosphatases,9.89460245404139e-06
abundance,9.89460245404139e-06
phosphatase,9.89460245404139e-06
antiprothrombinemic,9.89460245404139e-06
wethers,9.89460245404139e-06
6.4,9.89460245404139e-06
18-41,9.89460245404139e-06
11.4,9.89460245404139e-06
6.0,9.89460245404139e-06
toradoloral,9.89460245404139e-06
contributing,9.89460245404139e-06
ninds,9.89460245404139e-06
t-pa,9.89460245404139e-06
.002,9.89460245404139e-06
differed,9.89460245404139e-06
hyperplasia,9.89460245404139e-06
prostate-specific,9.89460245404139e-06
template,9.89460245404139e-06
.017,9.89460245404139e-06
pergolide,9.89460245404139e-06
electroretinograms,9.89460245404139e-06
survived,9.89460245404139e-06
layer,9.89460245404139e-06
retina,9.89460245404139e-06
outer,9.89460245404139e-06
adeno-associated,9.89460245404139e-06
wshow,9.89460245404139e-06
tunel,9.89460245404139e-06
efficiently,9.89460245404139e-06
vectors,9.89460245404139e-06
roles,9.89460245404139e-06
approved,9.89460245404139e-06
corticosteroid,9.89460245404139e-06
cbg,9.89460245404139e-06
dutp,9.89460245404139e-06
xenografts,9.89460245404139e-06
labelling,9.89460245404139e-06
-diethyl,9.89460245404139e-06
molecules,9.89460245404139e-06
deoxynucleotidyl,9.89460245404139e-06
ergosterol,9.89460245404139e-06
membrane,9.89460245404139e-06
lysing,9.89460245404139e-06
cyp4a11,9.89460245404139e-06
10-monohydroxy,9.89460245404139e-06
osteoarthritis,9.89460245404139e-06
benign,9.89460245404139e-06
shbg,9.89460245404139e-06
hormone-binding,9.89460245404139e-06
misused,9.89460245404139e-06
42.5,9.89460245404139e-06
1986,9.89460245404139e-06
3-hydroxy-3-methylglutaryl,9.89460245404139e-06
80-85,9.89460245404139e-06
6.13,9.89460245404139e-06
1.13,9.89460245404139e-06
5.5-fold,9.89460245404139e-06
vasopressor,9.89460245404139e-06
obstetric,9.89460245404139e-06
cerebrovascular,9.89460245404139e-06
accidents,9.89460245404139e-06
crushed,9.89460245404139e-06
time-dependent,9.89460245404139e-06
solubility,9.89460245404139e-06
nerves,9.89460245404139e-06
smooth,9.89460245404139e-06
clotibrate,9.89460245404139e-06
shimadzu,9.89460245404139e-06
detector,9.89460245404139e-06
pda,9.89460245404139e-06
nephrosis,9.89460245404139e-06
acromegaly,9.89460245404139e-06
u,9.89460245404139e-06
applying,9.89460245404139e-06
indications,9.89460245404139e-06
formulary,9.89460245404139e-06
tolerability,9.89460245404139e-06
cardiology,9.89460245404139e-06
86,9.89460245404139e-06
internal,9.89460245404139e-06
departments,9.89460245404139e-06
neuropathy,9.89460245404139e-06
5-methyltetrahydro-folate,9.89460245404139e-06
consulting,9.89460245404139e-06
illustrated,9.89460245404139e-06
metabolizer,9.89460245404139e-06
people,9.89460245404139e-06
vasculature,9.89460245404139e-06
"16,16-dimethylprostaglandin",9.89460245404139e-06
junction,9.89460245404139e-06
longterm,9.89460245404139e-06
underlying,9.89460245404139e-06
sensation,9.89460245404139e-06
incisive,9.89460245404139e-06
cardiotoxicity,9.89460245404139e-06
ketones,9.89460245404139e-06
bolus,9.89460245404139e-06
objectives,9.89460245404139e-06
neural,9.89460245404139e-06
representations,9.89460245404139e-06
photic,9.89460245404139e-06
tool,9.89460245404139e-06
acinar,9.89460245404139e-06
jaffe,9.89460245404139e-06
phosphorous,9.89460245404139e-06
wild-type,9.89460245404139e-06
toxicokinetic,9.89460245404139e-06
toxicologic,9.89460245404139e-06
bph,9.89460245404139e-06
5000,9.89460245404139e-06
masking,9.89460245404139e-06
supplemental,9.89460245404139e-06
mix,9.89460245404139e-06
postoperative,9.89460245404139e-06
volume-depleted,9.89460245404139e-06
marine,9.89460245404139e-06
csf,9.89460245404139e-06
constriction,9.89460245404139e-06
pupil,9.89460245404139e-06
postoperatively,9.89460245404139e-06
records,9.89460245404139e-06
retrospectively,9.89460245404139e-06
oncology,9.89460245404139e-06
repeatedly,9.89460245404139e-06
symptom,9.89460245404139e-06
prohibited,9.89460245404139e-06
5.1,9.89460245404139e-06
c129h223n3o54,9.89460245404139e-06
remain,9.89460245404139e-06
enter,9.89460245404139e-06
orders,9.89460245404139e-06
interpreted,9.89460245404139e-06
criteria,9.89460245404139e-06
palythoa,9.89460245404139e-06
pharmacology-pharmacokinetics-drug-drug,9.89460245404139e-06
administration-dosage,9.89460245404139e-06
sections,9.89460245404139e-06
tuberculosa,9.89460245404139e-06
ros,9.89460245404139e-06
phasic,9.89460245404139e-06
palytoxin-induced,9.89460245404139e-06
dual,9.89460245404139e-06
93,9.89460245404139e-06
corresponded,9.89460245404139e-06
hospital,9.89460245404139e-06
n=43,9.89460245404139e-06
pyrethroid,9.89460245404139e-06
pesticides,9.89460245404139e-06
oxygen,9.89460245404139e-06
coelenterates,9.89460245404139e-06
mg2+,9.89460245404139e-06
implants,9.89460245404139e-06
injectables,9.89460245404139e-06
broad,9.89460245404139e-06
rehospitalisation,9.89460245404139e-06
relapse,9.89460245404139e-06
scales,9.89460245404139e-06
rating,9.89460245404139e-06
growing,9.89460245404139e-06
zn-sepharose,9.89460245404139e-06
disrupts,9.89460245404139e-06
pointer,9.89460245404139e-06
goal-directed,9.89460245404139e-06
facilitates,9.89460245404139e-06
mu,9.89460245404139e-06
epsilon,9.89460245404139e-06
heat,9.89460245404139e-06
stimulus,9.89460245404139e-06
despite,9.89460245404139e-06
39.1,9.89460245404139e-06
gram-positive,9.89460245404139e-06
renin-angiotensin-aldosterone,9.89460245404139e-06
lasma,9.89460245404139e-06
poultry,9.89460245404139e-06
bw,9.89460245404139e-06
newcastle,9.89460245404139e-06
avian,9.89460245404139e-06
urticaria,9.89460245404139e-06
angioedema,9.89460245404139e-06
aggressive,9.89460245404139e-06
generalized,9.89460245404139e-06
oxaloacetate,9.89460245404139e-06
several-fold,9.89460245404139e-06
pharmacoeconomic,9.89460245404139e-06
aggression,9.89460245404139e-06
measures,9.89460245404139e-06
anxiety/depressive,9.89460245404139e-06
norfluoxe-tine,9.89460245404139e-06
strategies,9.89460245404139e-06
preceded,9.89460245404139e-06
homogenates,9.89460245404139e-06
atp,9.89460245404139e-06
progestational,9.89460245404139e-06
delayed-release,9.89460245404139e-06
survive,9.89460245404139e-06
shift,9.89460245404139e-06
carbodiimide,9.89460245404139e-06
aminotransferases,9.89460245404139e-06
30-fold,9.89460245404139e-06
micrograms/120,9.89460245404139e-06
mammary,9.89460245404139e-06
gly-buride,9.89460245404139e-06
pharmaco-dynamics,9.89460245404139e-06
negligible,9.89460245404139e-06
personality,9.89460245404139e-06
vascularity,9.89460245404139e-06
location,9.89460245404139e-06
apoptotic,9.89460245404139e-06
n-dodecyl,9.89460245404139e-06
tannic,9.89460245404139e-06
crude,9.89460245404139e-06
gallate,9.89460245404139e-06
235.1,9.89460245404139e-06
benzyl,9.89460245404139e-06
niddm,9.89460245404139e-06
bioequivalent,9.89460245404139e-06
drug/,9.89460245404139e-06
endocrine,9.89460245404139e-06
covalently,9.89460245404139e-06
explain,9.89460245404139e-06
oleate,9.89460245404139e-06
translocating,9.89460245404139e-06
translocation,9.89460245404139e-06
a-strain,9.89460245404139e-06
e-strain,9.89460245404139e-06
transferring,9.89460245404139e-06
attacks,9.89460245404139e-06
bacteria,9.89460245404139e-06
228.2,9.89460245404139e-06
30.8,9.89460245404139e-06
sd,9.89460245404139e-06
45-51,9.89460245404139e-06
45-52,9.89460245404139e-06
histologic,9.89460245404139e-06
rendered,9.89460245404139e-06
phosphohydrolase,9.89460245404139e-06
discernible,9.89460245404139e-06
drug-metab-olizing,9.89460245404139e-06
appearance,9.89460245404139e-06
folinic,9.89460245404139e-06
restored,9.89460245404139e-06
cleared,9.89460245404139e-06
wear,9.89460245404139e-06
off,9.89460245404139e-06
vice,9.89460245404139e-06
versa,9.89460245404139e-06
slows,9.89460245404139e-06
activate,9.89460245404139e-06
denudation,9.89460245404139e-06
independent,9.89460245404139e-06
noradrenaline-precontracted,9.89460245404139e-06
concentration-responses,9.89460245404139e-06
long-sedation,9.89460245404139e-06
detect,9.89460245404139e-06
date,9.89460245404139e-06
origins,9.89460245404139e-06
investigates,9.89460245404139e-06
treatment-emergent,9.89460245404139e-06
endothelium,9.89460245404139e-06
7.0,9.89460245404139e-06
chemically,9.89460245404139e-06
cyp450s,9.89460245404139e-06
beta-glucuronidase,9.89460245404139e-06
adequately,9.89460245404139e-06
47,9.89460245404139e-06
self-injection,9.89460245404139e-06
superimposed,9.89460245404139e-06
18-27,9.89460245404139e-06
follow,9.89460245404139e-06
transferase-mediated,9.89460245404139e-06
degrading,9.89460245404139e-06
virus-2,9.89460245404139e-06
low-molecular,9.89460245404139e-06
effected,9.89460245404139e-06
drug/laboratorytest,9.89460245404139e-06
bioassay,9.89460245404139e-06
lome-floxacin,9.89460245404139e-06
cytometry,9.89460245404139e-06
nick-end,9.89460245404139e-06
transfection,9.89460245404139e-06
precede,9.89460245404139e-06
needing,9.89460245404139e-06
respectto,9.89460245404139e-06
sst,9.89460245404139e-06
selected,9.89460245404139e-06
divergently,9.89460245404139e-06
rbc,9.89460245404139e-06
incombination,9.89460245404139e-06
placebo/day,9.89460245404139e-06
adjuvant,9.89460245404139e-06
promising,9.89460245404139e-06
494,9.89460245404139e-06
persist,9.89460245404139e-06
aspergillus,9.89460245404139e-06
bio-rad,9.89460245404139e-06
platelia,9.89460245404139e-06
piperacillin/tazobactam,9.89460245404139e-06
eia,9.89460245404139e-06
copper-reduction,9.89460245404139e-06
15-20,9.89460245404139e-06
first-episode,9.89460245404139e-06
cost,9.89460245404139e-06
borne,9.89460245404139e-06
expanders,9.89460245404139e-06
ambulatory,9.89460245404139e-06
hematopoiesis,9.89460245404139e-06
chemosensitizer,9.89460245404139e-06
in-vivo,9.89460245404139e-06
repeating,9.89460245404139e-06
conscious,9.89460245404139e-06
epidermal,9.89460245404139e-06
necrolysis,9.89460245404139e-06
2c8,9.89460245404139e-06
instead,9.89460245404139e-06
in-vitro,9.89460245404139e-06
sub-,9.89460245404139e-06
lst,9.89460245404139e-06
20th,9.89460245404139e-06
pentobarbital-induced,9.89460245404139e-06
sensitization,9.89460245404139e-06
andusing,9.89460245404139e-06
mayuse,9.89460245404139e-06
co-infected,9.89460245404139e-06
treatpatients,9.89460245404139e-06
2e1,9.89460245404139e-06
